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ABSTRACT

Kidney performs a complex task of concentrating the urine, retention of salts and protein
and excretion of metabolic toxins and by the virtue of its function, is always under the
chemical stress and subject to constant tissue damage. Post injury, nephrons have the
ability to regain their function by remodeling including, clearing of apoptotic and
necrotic

debris.

Kidney

Injury

Molecule-1(KIM-1/TIM-1/HAVCR-1)

is

a

phosphatidylserine receptor that recognizes the apoptotic bodies and directs them to the
lysosomal degradation. KIM-1 a type I transmembrane glycoprotein, although not
constitutively expressed, is expressed in injured epithelial cells. It is known that the
extracellular domain is cleaved by, MMP-9 and MMP-3, and the cleaved protein can be
detected in the urine, making it a sensitive and non-invasive biomarker of renal injury. In
rat renal injury model we observed neutrophil infiltration at the site of injury. To
understand the role of neutrophis and its relation to KIM-1, we hypothesized, activated
neutrophils increases shedding of the KIM-1 extracellular domain via MMP activity
and thus reducing the uptake and clearing of apoptotic bodies. The purpose of the
study is to determine if activated neutrophils can cause KIM-1 shedding and identify the
MMP involved in this cleavage. Immortalized human proximal tubular (HK2) cells were

v

treated with supernatant from PAF (pro-inflammatory lipid) activated neutrophils. We
observed an increase shedding of KIM-1 on treatment with activated neutrophil
supernatant and that shedding was blocked after pretreatment

of neutrophils with an MMP-9 inhibitor. Pretreatment with MMP-3 inhibitor did not
show any change. We also found KIM-1 mediated uptake of apoptotic bodies is reduced
after the KIM-1 ectodomain shedding .Our study suggests that activated neutrophils can
cause KIM-1 shedding via MMP-9 that consequentially reduces the phagocytic activity
of the epithelial cells and thus affect the kidney remodeling

vi
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CHAPTER I
INTRODUCTION

1.1 Acute renal failure and its significance
Acute Renal Failure (ARF), previously known as Acute Renal Injury or
Ischemic Renal Injury (IRI) (Bellomo et al., 2004), is a syndrome characterized by rapid
loss (ranging from hours to days) of kidney function with the accumulation of metabolic
wastes such as urea, creatinine, uric acid and many other metabolites. It is usually
associated with reduction in the urine output (not in all cases), increased serum potassium
and sodium concentrations, and increased metabolic acids (Bellomo et al., 2004). ARF
carries a high risk of both short-term and long-term mortality and morbidity (Ali et al.,
2007). Despite advances in pharmacological intervention, there is no marked reduction in
mortality and morbidity. Over the years, research has stressed the need for detecting ARF
in the early stages. Intervention at the early stages of the disease progression not only
reduces mortality and morbidity, but also favors better prognosis with complete
regeneration of the renal functions. Urinary MMP-9, IL18, NGAL, and KIM-1 are among
1

the renal injury biomarkers in different stages of investigation. Of these, KIM-1 has
emerged to be a very sensitive and specific biomarker for renal injury; it is better than
traditional markers such as serum creatinine and blood urea nitrogen (BUN) (Vaidya et
al., 2010). The pathogenesis of ARF is complex and involves endothelial and epithelial
cell death, alterations in microvascular blood flow, intra-tubular obstruction, and
immunological and inflammatory processes. Of the many components involved in this
complex mechanism, the role of infiltrating leuckocytes, especially neutrophils and the
epithelial cell death by apotosis and its clearance, are of special interest to this study. This
study ventures to explore the role of activated neutropils, their cross talk with other
molecules, and their effects on pathophysioloy of AFR and renal repair. Ischemic
reperfusion injury (IRI) is the most common etiology of ARF, and most of the
understanding of ARF comes from the murine model of IRI. Recent studies in the murine
model of IRI have demonstrated the role of apoptotic cells in inflammation, and the
importance of rapid clearing of apoptotic cells to prevent further inflammation and
immunological reactions (Kelly et al., 2001). KIM-1, apart from being a sensitive
biomarker, is suggested to play an important role in the pathogenesis and subsequent
renal repair. KIM-1 is a scavenger receptor, and is involved in the clearing of
apoptotic/necrotic bodies (Ichimura et al., 2008). This study is focused towards
understanding the role of activated neutrophils, medicated KIM-1 modulation, and its
overall affect on apoptotic/necrotic cell uptake and renal repair.

2

1.2 Current treatment modalities for ARF
The current treatment modalities for ARF can be broadly divided into nondialysis treatment and dialysis treatment. The non-dialysis treatment is focused on
reversing the underlying cause and reversing its metabolic consequences, which include
volume overload, solute overload (hyperkelemic acidosis; uremia), endocrine
deficiencies, and non-renal disturbances like GI bleeding, delirium, sepsis, respiratory
dysfunction, and cardiac arrest (Alkhunaizi and Schrier, 1996, Conger, 1995). Even with
the newer pharmacological agents like loop diuretics (Nigwekar and Waikar, 2011),
mannitol, Fenoldopam (dopamine-1 receptor agonist that decreases vascular resistance
and increases renal blood flow) (Denton et al., 1996), atrial natriuretic peptide (ANP)
(Allgren et al., 1997), and insulin-like growth factor -1 (Petrinec et al., 1996), there has
not been any significant reduction in mortality and morbidity associated with ARF or
improvement of renal regeneration (Westenfelder, 2011).
Dialysis therapy, or renal replacement therapy (RRT), includes continuous renal
replacement therapy (CRRT) and intermittent renal replacement therapy (IRRT). 70% of
all patients with ARF in the intensive care unit require RRT (Davenport et al., 1991).
IRRT has been the only available mode of therapy. The disadvantage of this procedure is
that it is not well tolerated by patients with hemodynamic instability. CCRT, which was
first introduced in 1977, involves slow and continuous dialysis, and it is well tolerated by
most patients. However, it has the disadvantage of being a complicated, expensive
procedure and carries increased risk of infections. Many non-randomized and
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retrospective studies in comparing CRRT vs. IRRT have shown no significant differences
in the mortality rates of the patients (Kellum et al., 2002). Even with the RRT therapy,
the mortality is as high as 50% in critically ill patients (Star, 1998). This suggests a need
for better understanding of the molecular mechanism of ARF and developing novel
therapies aimed at improving renal regeneration. KIM-1, a scavenger receptor, may play
an important role in renal regeneration and hence, better understanding of its molecular
mechanism and exploiting it as a treatment modality are prime goals of this study.

1.3 Hypothesis and specific aims
Neutrophils play an important role in the pathogenesis of ARF. The goal of this
study is to understand the interaction of neutrophils with KIM-1 and its role in
pathogenesis and epithelial cell repair. Hence we hypothesized: activated neutrophils
increase the KIM-1 ectodomain shedding via MMP-9 activity and thereby reduce
the uptake of apoptotic bodies by renal tubular epithelial cells.
Specific aim 1) Understand the role of neutrophils in KIM-1 modulation. Determine if
activated neutrophils mediate KIM-1 ectodomain shedding.
Specific aim 2) Determine the effect of neutrophils on KIM-1 mediated apoptotic cell
uptake.
Specific aim 3) Identify the matrix metalloproteinase (MMP) involved in the cleavage of
the KIM-1 ectodomain.

4

1.4 Organization of thesis
Chapter II provides detailed background information on etiology and
pathogenesis of ARF, and the role of leukocytes and apoptotic/necrotic cells in the
inflammation process; KIM-1 structure, expression, and renal and extra-renal functions of
KIM-1. The mechanism of renal regeneration, the role of KIM-1 in clearing the
apoptotic/necrotic cells, and possible role in renal regeneration will be discussed.
Relevant anatomy and the physiological role of the kidney will also be discussed.
Materials and methods used in this study will be discussed in chapter III. The results
obtained from these experiments will be discussed in chapter IV. Conclusions and future
directions will be discussed in chapter V.

5

CHAPTER II
BACKGROUND
2.1 Kidney
2.1.1 Gross anatomy of the kidney
The kidney is one of the most versatile organs in the body, performing several
essential and regulatory functions. It is one of the vital components of the human urinary
system. Human healthy kidneys are reddish brown in color and are situated behind the
peritoneum on either side of the vertebral column. Figure 1 depicts the gross anatomy of
the kidney. The upper border of the kidney is marked at the level of the 12th thoracic
vertebra and the lower border at the 3rd lumbar vertebra. The right kidney lies about 1cm
lower than the right kidney to accommodate the liver. The dimensions of adult kidneys
are approximately 11cm X 6cm X 3cm, and it weighs about 150 grams in males and 135
grams in females. The internal microstructure of the kidney can be divided into an
internal medulla and an external cortex. The renal medulla consists of pale, striated,
conical renal pyramids with a peripheral base and apices converging towards papillary
sinuses. The subcapsular renal cortex arches over the base of the pyramids. It is divided
6

from the medulla by tangential blood vessels. The cortex can be histologically divided
into outer and inner cortexes. The cortex closest to the medulla is sometimes referred to
as the juxtamedullary cortex. The renal artery, a direct branch of the abdominal aorta,
supplies about 20% of the total cardiac output to the pair of kidneys. The renal artery
divides into lobar arteries, which supply each pyramid. These further divide into
interlobar, arcuate, and interlobular arteries. The lateral rami of the interlobular arteries
continue as afferent arterioles, which carry the blood through the glomuruli and efferent
arterioles carry the filtered blood away from the glomeruli. The venous drainage is by the
renal veins, which drain to the inferior vena cava (Standring S 2009).

Figure

1:

Gross

anatomy

of

human

http://www.infobarrel.com/External_Anatomy_of_the_Kidney
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kidney.

Adopted

from

2.2 Nephron
A nephron comprises the functional unit of the kidney, and each kidney consists
of about 1 million nephrons. The parts of the nephron are shown in Figure 2.

Figure 2: Parts of nephron. Adopted from www. holzbau-brunner.de
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2.2.1 Glomerulus
A glomerulus is a collection of convoluted capillary blood vessels supported by a
delicate mesh of mesangial matrix. The tuft of capillaries creates a mesh to filter the
blood carried in by the afferent arteriole. Filtrate formed moves to the tubules and the
filtered blood exits the glomerulus by the efferent arteriole (Standring S 2009).
2.2.2 Bowman’s capsule
Bowman’s capsule is the blind expanded end of a renal tubule. It consists of
simple squamous epithelial cells on its outer wall and the inner wall is made of
specialized epithelial podocytes. Podocytes are stellate cells with foot processes that
branch and give rise to terminal pedicles. These pedicles form a tight junction between
the neighboring pedicles, and form a narrow slit between two pedicles called the filtration
slit. The filtration slit is lined by a dense membranous slit diaphragm, through which the
filtrate must pass to enter the urinary space (Standring S 2009).
2.2.3 Renal tubule
The renal tubule consists of a glomerular capsule that continues as a proximal
tubule, connected by a small neck. The proximal tubule continues as a coiled or
convoluted tubule. As this approaches the medulla, it straightens and becomes the
descending thin limb of the loop of Henle, and with an abrupt U-turn, continues as the
ascending limb of Henle. Deep in the medulla, the tubules are narrower and the walls are
thin. These sections are called descending and ascending thin segments of Henle’s loop
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respectively. The ascending thick limb of Henle continues as the distil tubule and reenters the medulla. The distil tubule then continues as the convoluted distal tubule, and
finally straightens out again to form the connecting tubule to join the collecting ducts.
The renal tubules are lined by single layered epithelial cells, and the type of
epithelial cells varies according to the region and function. Proximal tubules are lined by
cuboidal, or low columnar epithelial cells, with brush border of tall microvilli on its
luminal surface, and basal cytoplasm, which is rich in mitochondria. The microvilli on
the luminal surface increase the surface area in contact with the tubular fluid. Abundant
mitochondria provide the ATP required for medullary transportation and reabsorption of
ions and small molecules against the concentration gradient.
Renal tubules, based on their marked differences in structure, histology, and
function, can also be divided into three segments: namely S1, S2, and S3. All three
segments are characterized by unique cell type. S1 and most of the S2 segment comprises
the proximal convoluted tubule. A sharp transition in the cell type from the convoluted
part to the straight part of the tubule marks the boundaries of S3 segment (Standring S
2009).

2.3 Functions of kidney
Kidney performs a wide range of functions, from excretion of metabolic wastes
to maintaining the normal homeostasis of the total body fluid, volume, or acid-base
contents. These functions are carried out independently, or in orchestration with the many
hormones secreted by the kidney. The major functions of the kidney are as follows:
10

A. Excretory functions: Kidney is involved in the production, concentration, and
excretion of the metabolic wastes like urea, uric acid, and creatinine.
B. Osmolality regulation: Kidney regulates the osmolality, or total body fluid, by
regulating the water contents of urine; i.e., when plasma osmolality drops, kidney
increases water reabsorption, and secretes concentrated urine. Similarly, when the
plasma osmolality increases, the kidney secretes dilute urine, and thus maintains
the total body fluid. This function is under strict control of antidiuretic hormone,
secreted by the posterior pituitary gland. The hormone increases the vascular
permeability of the collecting duct, thus secreting dilute urine.
C. Acid base homeostasis: Kidney and lungs are the principle organs involved in the
regulation of acid base balance and maintenance of pH in permissible levels.
Kidneys maintain the pH levels by reabsorbing the bicarbonate ions or excreting
H+ ions.
D. Blood pressure regulation: Kidneys are involved in the maintenance and
regulation of blood pressure by regulating the reabsorption of sodium chloride.
This, in turn, is controlled by renin, a hormone secreted from kidney, which is a
part of renin-angiotensin pathway.
E. Hormone secretion: Kidney secretes a variety of hormones, including
erythropoietin and enzymes like renin. In response to hypoxia, erythropoietin is
secreted, which stimulates the bone marrow for increased erythropoiesis.
Calcitrol, an active form of vitamin D, facilitates absorption of calcium in the
intestine and renal phosphate reabsorption. It is also involved in maintenance of
bone calcium deposition.

11

F. 2.4 Epidemiology of acute renal failure
The global burden of ARF and the complications associated with it are increasing.
A recent epidemiological study from Scotland shows incidence of ARF as 2147 per
million population per year (PMP) (Ali et al., 2007), and a large community based study
in the United States shows incidence of ARF over 5000 PMP requiring no dialysis, and
over 2915 PMP requiring dialysis (Hsu et al., 2007). The rate of ARF increases
drastically in critically ill patients, with a reported rate of 67% in patients admitted to
intensive care facility, and a frequency of 1.9% in all hospital admissions (Hoste et al.,
2006). ARF is a very important cause for mortality and morbidity in hospitalized patients,
with an adjusted mortality risk of 1.4 (Lafrance and Miller, 2010). Mortality of patients
developing post-operative ARF ranges 24-100% and 50-70% in patients in intensive care
facility on dialysis (Zanardo et al., 1994, Spiegel et al., 1991). 20-60% of patients with
ARF require dialysis, and of the subgroup surviving the initial dialysis, only 25%
required lifelong dialysis (Pascual et al., 1990). This shows that the syndrome can be
reversed, and that the kidney possesses the property of regeneration.

2.5 Etiology of acute renal failure
ARF can result from a wide range of insults to the body. In a hospital setting,
ARF is common in elderly, newborns, or patients with other serious debilitating
conditions. It is usually associated with multi-organ failure, sepsis, patients on
nephrotoxic drugs, and administration of radio contrast dye. The common etiological
factors have been depicted in Figure 3.
12

Figure 3 Etiology of acute renal failure. The figure shows, most important causes of ARF.
Modified from (Lameire et al., 2005)

2.5.1 Pre-renal causes
Reduction in the perfusion of the kidney with intact tubular and glomerular
function results in the reduction of renal clearance, is called pre-renal failure or pre-renal
azotemia. The most common causes include severe dehydration due to diarrhea, use of
diuretics, excessive vomiting, and cardiac failure (Brater, 2002, Gambaro and Perazella,
13

2003). Elderly people and newborns are particularly susceptible, owing to pre-existing
hypovolemia state (Himmelfarb, 2009). The kidney responds to reduction in the renal
perfusion or pressure, by auto-regulating glomerular filteration rate (GFR) and renal
blood flow. When the pre-glomerular pressure drops gradually, the kidney maintains a
constant glomerular capillary hydrostatic pressure by secreting vasodilatating agents like
prostaglandin I2 (Baylis and Brenner, 1978) and NO2 (De Nicola et al., 1992). A
tubuloglomerular feedback mechanism maintains the GFR and the fluid delivery to the
distil nephron. In case of acute fluid loss, there is an increased fluid absorbtion from the
proximal tubule, and the tubuloglomerular feedback mechanism mitigates a reduction in
GRF (Blantz, 1998, Badr and Ichikawa, 1988). In patients with reduced renal perfusion,
non-steroidal anti inflammatory drugs (NSAIDS) are known to precipitate pre-renal
azotemia (Shankel et al., 1992). Drugs like cyclosporine and tacrolimus cause
vasoconstriction of small renal vessels leading to pre-renal azotemia (Textor et al., 1993).
ACE inhibitors or ACE receptor blockers are also known to precipitate pre-renal
azotemia (Franklin and Smith, 1986). In hospital settings, patients with septic shock,
cardiac failure, liver diseases, or multi-organ failure are at high risk (MacDowall et al.,
1998) to suffer from pre-renal azotemia. In surgical cases, postoperative and
perioperative renal dysfunction, reduction in the mean arterial blood pressure, and
reduction in the effective blood volume due to anesthesia, lead to pre-renal azotemia
(Shusterman et al., 1987).

14

2.5.2 Renal or intrinsic causes.
Renal azotemia is associated with some cellular injury. The renal failure is
characterized based on the site of the insult: glomerulus, vessels, interstitium, or tubules.
And of these, tubular necrosis accounts for about 70% of all the cases (Nash et al., 2002),
and 50% of tubular necrosis is caused by ischemic injuries. Tubular ischemic injury is
usually a continuation of pre-renal azotemia, where the blood supply to the tubule is
severely compromised, leading to necrosis of the tubular cells. The ischemic tubular
necrosis can be reversed on early detection and by treating the root cause.
Toxic injury counts as the second most common cause of intrinsic renal failure,
accounting for about 20% of all the renal failure cases (Pannu and Nadim, 2008). The
most common drugs causing failure, but not limited to these, include aminoglycoside
antibiotics, radio contrast dyes, heme pigments, NSAIDS, chemotherapeutic agents like
cisplatin, and myeloid light chain proteins (Liangos, 2012). The toxins act directly on
cells or through another mechanism, damaging them. The mechanisms of action of most
common nephrotoxic drugs are discussed in Table 1. Ischemia and toxins often combine
to cause acute renal failure in severely ill patients with conditions such as sepsis,
hematologic cancers, or the acquired immunodeficiency syndrome (Rao and Friedman,
1995).

15

Mechanism of action

Drug

Reduction in renal perfusion
through alteration of intrarenal
hemodynamics
Direct tubular toxicity

NSAIDs, angiotensin-convertingĞenzyme
inhibitors, cyclosporine, tacrolimus,
radiocontrast
Aminoglycoside antibiotics, radiocontrast
agents, cisplatin, cyclosporine, tacrolimus,
amphotericin B, methotrexate,
foscarnet, pentamidine, organic solvents,
heavy metals, intravenous immune
globulin
Cocaine, ethanol, lovastatin

Heme-pigmentĞinduced tubular
toxicity (rhabdomyolysis)
Intratubular obstruction by precipitation
of the agent or its
metabolites or by-products
Allergic interstitial nephritis

HemolyticĞuremic syndrome

Acyclovir, sulfonamides, ethylene glycol,
chemotherapeutic agents,methotrexate
Penicillins, cephalosporins, sulfonamides,
rifampin, ciprofloxacin, NSAIDs, thiazide
diuretics, furosemide, cimetidine,
phenytoin, allopurinol
Cyclosporine, tacrolimus, mitomycin, cocaine,
quinine, conjugated estrogens

Table 1: Mechanism of action of common nephrotoxic drugs. Adopted from
(Thadhani et al., 1996)

Interstitial nephritis, glomerular nephritis, and vascular nephritis represent a very
small percentage of all the ARF cases. Interstitial nephritis is most commonly caused by
drug reaction. The other less frequent causes include autoimmune disease like lupus,
infiltrating disease like amylodosis, and many viral infections (Cameron, 1988).
Glomerular nephritis is mostly secondary to autoimmune diseases. Malignant
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hypertension and vasculitis are the common reason for vascular nephritis (Graciano et al.,
2007). Interstitial nephritis and glomerular nephritis are also reversible in most cases, and
corticosteroids are known to hasten the recovery.

2.5.3 Post -renal causes
Obstruction to the urinary outflow at the level of the kidney or further down the
urinary tract leads to increased backpressure on the kidney, resulting in structural and
functional damage to the kidney. The most common causes include obstruction of the
urethra by prostatic hypertrophy, prostatic cancer, or cervical cancer (Feest et al., 1993).
Other less frequent causes include bilateral kidney stones, blood clots, fungal infections,
retroperitoneal infection, colon and rectal carcinoma.

2.6 Pathophysiology of acute renal failure
Acute renal failure is a complex dynamic process, involving a cross-talk between
the tubular epithelial cells (Ueda and Shah, 2000), basement membrane, extra cellular
matrix, infiltrating leukocytes (Okusa, 2002), and vascular factors (Sutton et al., 2002).
This discussion will be limited to acute tubular necrosis from ischemia/toxic injury,
which, as mentioned in the section 2.5.2, accounts for more than 90% of all the ARF
cases. Interestingly, tubular epithelial cell are particularly vulnerable to injury (Havasi
and Borkan, 2011), more than any other cell in the nephron. In this section, the
pathophysiology of acute tubular necrosis, especially resulting from ischemic renal
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injury, will be discussed in detail. Pathophysiology of other non-common causes such as
interstitial necrosis and glomerular nephritis, are complex and usually immune-cellmediated (Falk and Jennette, 2010, Glassock, 2010, Lightstone, 2010) and will be beyond
the scope of this study.
Most of our understanding of pathophysiology of acute tubular necrosis comes
from the well-established mouse ischemia/reperfusion model (Wei and Dong, 2012).
Although this model has its limitations, as the tubular injury resulting from sepsis or toxic
insults are not explained (Ishikawa et al., 2010), it does give us a clear understanding of
tubular necrosis secondary to pre-renal causes.
Following an ischemic insult, the complement system is activated; predominantly
by an alternative pathway (Thurman et al., 2005). Complement up-regulates the
endothelial binding proteins, receptors for collagen-like (cC1qR) and globular domains
(gC1qR) of complement C1q (Guo et al., 1999). Complement also activates dendritic
cells (DC) and C3 (macrophage derived complement protein) binding to the endothelial
cells. The activated DCs in turn activate T cells (Sandor et al., 2009). Complement
receptor 1-related protein y (Crry), a complement inhibitor, is expressed by the basement
membrane of the proximal tubular cells (Thurman et al., 2006b). Loss of polarity and
destruction of the basement membrane leads to altered expression of Crry. The inability
of Crry to inhibit the complement is the key in activation of complement (Thurman et al.,
2006a). Crry deficient mice, as would be expected, are more susceptible to IRI (Thurman
et al., 2006a). In tubular necrosis, tubular epithelial cells are not innocent victims of
injury, but play an active role in the inflammation process. They not only generate proinflammatory cytokines like TNF-α, MCP-1, IL-8, IL-6, IL-1β, TGF-β, RANTES, and
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epithelial neutrophil-activating protein 78 (ENA-78), which activate inflammatory cells;
they also express Toll-like receptors (TLRs), complement and complement receptors, and
molecules that regulate T lymphocyte activity (Bonventre and Zuk, 2004). TLRs are
transmembrane receptors widely expressed in leukocytes and renal epithelial cells.
Increased expression of TLR-2 and TLR-4 and increased neutrophil infiltration has been
observed during ischemic injury. TLR-4(-/-) mice with wild type mice bone marrow graft
showed significantly less serum creatinine and histological tubular necrosis compared to
wildtype mice with TLR-4(-/-) bone marrow graft after an IRI (Pulskens et al., 2008).
Similarly, cisplatin treatment in mice with a targeted deletion of TLR-2, demonstrated
reduced renal dysfunction, tubular necrosis serum, urinary cytokines, and chemokines
compared to mice expessing TLR -2 (Zhang et al., 2008a).
Tubular epithelial cells undergo a series of alterations, as depicted in Figure 4,
finally resulting in necrosis or apoptosis. Ischemia results in extensive damage to the
basement membrane with a rapid loss of cytoskeletal integrity (Lameire et al., 2005).
Apical membranes are damaged with the shedding of the proximal tubular brush border
(Solez et al., 1979). This is followed by mislocalization of cell adhesion molecules and
other membrane proteins like Na+K+ATPase and β-integrins (Gailit et al., 1993, Zuk et
al., 1998). ATP depletion leads to an increase in intercellular free calcium concentrations,
resulting in activation of proteases and phospholipases, which in turn contribute to further
disruption of the cytoskeleton and impair mitochondrial energy metabolism interfering
with production of ATP (Bonventre, 1993). Na+K+ATPase maintains the cell volume and
cell polarity by maintaining a negative intracellular charge and low Na+ concentrations.
With depletion of oxygen and ATP, Na+K+ATPase ceases to function, leading to an
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increase Na+ and Cl- concentration with a loss of cell polarity (Leaf, 1959, Flores et al.,
1972). β-integrin dependent cell-cell, cell-matrix adhesions are disrupted by cytokines
and with superimposed ATP depletion, results in disruption of cell–cell junctional
complexes (Zuk et al., 1998). Disruption of the tight junction alters both cell permeability
and cell polarity (Abbate et al., 1994). Loss of cell membrane integrity leads to swelling
of the cells. The swollen cells block the lumen and further reduce the blood supply to
already ischemic cells (Linshaw et al., 1991). This ultimately leads to activation of the
apoptosis pathway. The dead and living cells slough into the lumen forming casts. The
casts are known to block the lumen, increase the intertubular pressure, and reduce the
glomerular filtration rate. The increase in permeability also results in back-leak of
glomerular filtrates. In rat renal ischemia/reperfusion models, the majority of luminal
cells were apoptotic or necrotic cell debris (Ichimura et al., 1995). These apoptotic and
necrotic cells were gradually cleared as the kidney regenerated (Borregaard and Cowland,
1997).
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Figure 4: Tubular epithelial cell injury and repair in ischemic reperfusion injury. Modified
from (Thadhani et al., 1996)

2.6.1 Role of inflammatory cells in pathogenesis of ARF
Inflammatory cells also play an important role in the pathogenesis of ARF. The
roles of neutrophils, macrophages, dendritic cells, and lymphocytes in pathogenesis of
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ARF are the subject of active research. However roles of lymphocytes, dendritic cells, T
cells, and B cells remain controversial and are beyond the scope of this discussion. Only
the role of neutrophils and macrophages in the pathogenesis of ARF will be discussed in
detail.
Neutrophils constitute the majority of white blood cells, and are the first
responders to the site of injury. Infiltration of neutrophils during ischemic injury has been
demonstrated in large number mice and human renal biopsies (Furuichi et al., 2002,
Miyazawa et al., 2002, Willinger et al., 1992, Linas et al., 1992). Though the role of
neutrophils in the pathogenesis of ARF is still not clearly understood, mice depleted of
peripheral circulating neutrophils were less susceptible to ischemic renal injury (Kelly et
al., 1996). Neutrophils adhere to the endothelial cells through a complex mechanism
involving several classes of adhesion molecules, which includes selectins, mucins,
integrins, and the Ig superfamily of proteins (Rabb et al., 1997). After neutrophils adhere
to the endothelial cells and chemotax ouside the vessel, they release reactive oxygen
species (ROS), proteases, elastase, myeloperoxidase, and matrix metalloproteinases that
further increase inflammation (Rabb et al., 1997). Chemokines and selectins are
upregulated by cytokines like IL-1 and TNFα. Then chemokines recruit leukocytes and
activate them, increasing adhesion (Rahman et al., 1998). Circulating or locally produced
TNFα and ROS produced during reperfusion injury is also known to recruit neutrophils
(Ishibashi et al., 1999). Transgenic mice overproducing anti-oxidants show less
histological injury and reduced neutrophil infiltration compared to wildtype mice
(Ishibashi et al., 1999). Of the many adhesion molecules involved, ICAM-1 has been
studied in detail; blocking ICAM -1 by injecting anit-ICAM-1 antibody, beneficial effects
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were observed in mice subjected to renal ischemia (Kelly et al., 1994). Similarly, ICAM1 knockout mice also demonstrated reduced tubular necrosis and serum creatine, versus
wild type mice subjected to ischemic injury (Kelly et al., 1996). After activation,
neutrophils are known to secrete matrix metalloproteinases (MMP). In fact, neutrophils
are considered the major source of MMPs in kidney, and are associated with many
diseases like pylonephritis and renal tissue scarring (Tan and Liu, 2012). MMPs from
neutrophils are particularly of great interest to this study, as some family members have
the ability to cleave a transmembrane protein expressed from the injured tubular cells
known as kidney injury molecule -1(KIM-1) (Ichimura et al., 1998). The role of KIM-1
and KIM-1 ectodomain shedding in relation to renal injury and regeneration will be
discussed in detail in section 2.11.
Macrophages are derived from blood monocytes. Apart from their role as
phagocytes, they are also known to secrete NO from iNOS and proinflammatory
cytokines including IL-18, IL-1α, IL1β, TNF α, and Nk-kB (Akcay et al., 2009).
Macrophage infiltration is observed at different stages of ARF. At early stages of AKI,
they are known to increase inflammation due to their pro-inflammatory cytokines (Li et
al., 2008); whereas, in the later stages they exhibit protective functions, clearing the
apoptotic cells by phagocytosis and secreting anit-inflammatory cytokines (Lee et al.,
2011). Depletion of macrophages using genetic techniques (Furuichi et al., 2003) or
liposomal colodronate (Ferenbach et al., 2012) during AKI, has demonstrated beneficial
effects; however, in a different study, depletion of macrophages in cisplatin-induced AKI
had no protective effects (Lu et al., 2008). Macrophage phenotype also determines their
role; M1 macrophages have pro-inflammatory effects, while M2 macrophages have
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protective function (Lee et al., 2011). Hence, further studies are required to understand
the exact functions of macrophages in AKI.

2.6.2 Apoptotic cells and inflammation
Apoptotic cells produced as a result of various insults need to be cleared by
physical removal, and this represents the final stage in apoptosis programming (Kerr et
al., 1972). Accumulation of apoptotic cells in the lumen not only blocks the lumen and
reduces the GFR, but also promotes secondary inflammation. Apoptotic cells are selfcontained, and thus prevent the release of intracellular contents. However, if they are not
cleared rapidly, they lose their cell membrane integrity; and, over time, release their
intracellular contents, which can provoke secondary inflammation and autoimmunity in
the tissue (Daemen et al., 1999). Studies in the murine model of ischemic reperfusion
injury show administration of IGF-1 (a growth and survival factor) and active caspase
inhibitor reduced inflammation; and this is most likely because of their ability to inhibit
apoptosis (Daemen et al., 1999). These findings strongly suggest that apoptotic cell death,
either directly or indirectly, contributes to inflammation and autoimmune reaction.
Professional phagocytes, such as macrophages, dendritic cells, and non-professional
phagocytes surrounding epithelial and endothelial cells, perform an important role in
clearing these cells. They are usually very efficient and rapid in clearing
necrotic/apoptotic bodies (Lauber et al., 2004); and thereby reduce secondary
inflammation. In the early stages of apoptosis, cells release ‘find-me’ signals, which
include many chemokines. The chemokines attract the motile phagocytes to the cells
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undergoing apoptosis. In the later stages of apoptosis, the cells express molecules like
phosphatidylserine (PS), which are termed as ‘eat-me’ signals (Ravichandran and Lorenz,
2007). Among the array of eat-me signals, exposure of PS on the cell surface, which is
otherwise on the inner surface of a healthy cell, is the key signal recognized by the
phagocytic cells. The phagocytic cells identify and bind to these ‘eat-me’ signals on
apoptotic bodies, and mediate their uptake (Peiser et al., 2002, Pearson, 1996).
Macrophages also help in attenuating the inflammation by secreting the antiinflammatory cytokine IL10, and reparative growth factors including TGF-β (Savill and
Fadok, 2000). Uptake of apoptotic cells by non-professional phagocytes has also been
shown to secrete growth-promoting factors and thus reduce further injury. Mouse
mammary epithelial cells, involved in the clearing of the apoptotic Jurkat-T cells,
secreted hepatocyte growth factor, TGF-β and VEGF, and also primed the cells to resist
UV induced cell injury (Golpon et al., 2004). In a similar study in mice, administration
of excessive apoptotic cells, or masking the PS via annexinV (to prevent the PS mediated
uptake) in the mice, produced the hallmark of autoimmunity, such as autoantibody
production and deposition of IgG in glomurulus (Asano et al., 2004). Defective clearing
of apoptotic cells depicts strong relation with the development of autoimmune disorders
like lupus, and it is due to development of antinuclear antibody against the chromatin
from the ruptured apoptotic cells (Taylor et al., 2000).
apoptotic/necrotic cells is necessary to attenuate the inflammation.
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Hence, clearing of

2.7 Tubular epithelial cell regeneration and apoptotic cell clearance
Unlike the heart or brain, kidney possesses the capability to recover completely
from ischemic or toxic injury. As mentioned in earlier sections, proximal tubular necrosis
comprises the majority of ARF cases. Hence, this discussion is limited to the events
following tubular damage: i.e. regeneration and proliferation of the surviving proximal
tubular epithelial cells, and the regaining of renal functions. After injury, surviving
epithelial cells undergo a series of alterations before they can function at their normal
capacity. Although the exact mechanism of the renal regeneration remains elusive, a
series of studies over years has emphasized the role of apoptotic cell clearing and renal
regeneration. Many theories have been proposed to identify the source of the cells that
are involved in the replacement of the dead cells. First, the new cells could be produced
from the resident stem cells (Oliver et al., 2004). Stem cells are self-renewing; i.e. can
produce more cells of their own kind by division. They also have the capability to
differentiate into different cell types by asymmetric division (Tanaka and Reddien, 2011).
Extensive experiments using genetic–fate mapping techniques have demonstrated the
absence of marrow-derived or renal interstitial cell-derived epithelial stem cells involved
in the reparative process (Humphreys et al., 2008). Second, there are specialized
progenitor cells, which have only a limited self-renewal property; they differentiate along
one particular cell lineage. Using unbiased DNA analog-based lineage identification in a
mouse model subjected to IRI, it was confirmed that no special progenitor cells were
involved in the repair of the renal epithelial cells (Humphreys et al., 2011). Third, the
surviving epithelial cells dedifferentiate to cover the loss of the neighboring cells (Pawar
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et al., 1995). Of the three possible hypotheses, dedifferentiation and proliferation of
surviving epithelial cells seem to the accepted mechanism.

2.8 Mechanism of renal proximal tubular epithelial cell regeneration
During homeostasis, kidney proximal tubular cells exhibit minimal proliferation
as

demonstrated

by

proliferative

cell

nuclear

antigen

(PCNA)

and

Ki-67

immunoreactivity (Nadasdy et al., 1994, Messier and Leblond, 1960). The proliferation is
under a rigid control, and is limited to just replace the cells lost into the urine. Post injury,
surviving epithelial cells rapidly enter the cell cycle and extensively proliferate to make
up for the loss of the neighboring cells (Witzgall et al., 1994). The mechanism of renal
repair is depicted in Figure 5. The crucial processes involved in the regeneration process
are migration, proliferation, and recuperation of physiological functions.
The functional recovery of the nephron begins with the migration of the
surviving epithelial cells. The mechanical scrape technique is the most widely used
method to mimic the tubular epithelial cell loss. In this technique, a tract of cells is
scraped from the confluent monolayer, and the capability of the surrounding cells to
migrate and cover the tract is measured. Using these techniques, rabbit proximal tubular
epithelial cells were scraped. It was observed that 77% of the scraped area recovered
within 7 days with no treatment; whereas epidermal growth factor (EGF) stimulated more
complete recovery, TGFβ inhibited the recovery. It was also observed that when the cells
were treated with known neprotoxins like mercuric chloride or fumonoisin, they
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displayed migratory defects and overall cytotoxicity. These results suggest the
importance of migration in renal repair (Counts et al., 1995).
Dedifferentiation is a property of rapidly dividing epithelial cells. The cells
dedifferentiate to attain the gene expression pattern seen in the developing nephron,
which has a major implication for regulation of renal repair. The dedifferentiation process
in renal tubular epithelial cells is associated with an up-regulation of genes encoding Egr1, c-fos, NAK-1, c-myc, and heat shock protein-70 (HSP-70) (Counts et al., 1995).
Several developmental genes like vimentine and Pax2, are also re-expressed (Basile et
al., 1997). Vimentin is an intermediate filament protein found in the undifferentiated
mesenchymal cell, otherwise not found in the adult kidney, and it is also a marker for
dedifferentiated epithelial cells. Cell adhesion molecules also play an important role in
the migration and dedifferentiation process. α6β1 intigrin (Kreidberg and Symons, 2000),
neural cell adhesion molecule (NCAM) (Acheson et al., 1991), and leukocyte-endothelial
adhesion molecule are the most important cell adhesion molecules in the adult proximal
tubular epithelial cell. After ischemic injury, β1 integrin relocates to the lateral border,
facilitating cell-cell and cell-matrix interaction (Zuk and Matlin, 2002). NCAM, a
member of Ig superfamily of proteins, controls the cell polarity and cell shape (Walsh
and Doherty, 1997). NCAM is also used as a marker for dediffrentation phenotype
metanephric mesynchyme (Bokel and Brown, 2002).
The role of extra cellular matrix (ECM) cannot be overstressed. ECM not only
provides a scaffold for the proliferating and migrating epithelial cells, many signaling
pathways are also activated by the interaction of ECM molecules with integrins. Postischemic insult, there is an increased production of ECM components including type IV
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collagen α1 chain and fibronectin, containing the extra type III (EIIIA) domain, and their
activity is detected in the basement membrane of the proliferating epithelial cells (Basile
et al., 1998). It is further confirmed by the finding that splice variants of fibrinonectinEIIIA are minimal in the normal kidney, but significantly increased after IRI (Zuk et al.,
2001), which suggests the fibrinonectin-EIIIA involvement in the renal regeneration.
Similarly, lamilin 5, which is known to be involved in the regeneration of skin wounds, is
proposed to be involved in renal regeneration. It is widely expressed along the basement
membrane of the nephron.
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Figure 5: Mechanism of renal regeneration. Figure adopted from (Tadani, et.al., 2008) RTPCRenal proximal tubular epithelial cells
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2.9 KIM-1/TIM-1/HAVCAR-1
The same protein has been separately identified in different processes, and so
identified by different names. When expressed in kidney, particularly proximal tubular
epithelial cells, it is called kidney injury molecule -1(KIM-1); similarly, when expressed
on T cells, it is called T cell immunoglobulin mucin domain-1 (TIM-1), and in liver it is
known as hepatitis A virus cellular receptor -1. In the following sections, structure,
function, and role of KIM-1 in renal regeneration will be discussed in detail.

2.9.1 Structure of KIM-1
KIM-1 is a type I transmembrane glycoprotein, and structurally resembles
mucosal addressin cell adhesion molecule (MAdCAM-1) (Briskin et al., 1993). KIM-1
has an extra cellular domain, a transmembrane domain, and a cytoplasmic tail. The
ectodomain, consisting of 100 residues, has an immunoglobulin V (Ig-V), made of highly
conserved 6 cystine residues, similar to what is found in immunoglobulin superfamily
(IgSF). It also contains a region rich in Thr/Ser/Pro with O-linked glycosylation, a
characteristic of mucin like domain. Many N-linked glycosylation are also present (Bailly
et al., 2002). The crystal structure of KIM-1 reveals the IgV domain to be made up of 2
anti-parallel β- sheets (BED and GFC) with four cystine residues joining a CC’ loop to
the GFC β- sheet which forms a pocket that recognizes phosphatidylserine (PS) (Su et al.,
2008). This binding cleft is unique for KIM-1, and is not found in other molecules of
immunoglobulin super family. The ability of KIM-1 to bind to the phosphatidylserine
suggests an important function in recognition of apoptotic cells. The transmembrane
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domain consists of 20 residues, but specific functions of the transmembrane domain are
still unknown. The C terminal or the cytoplasmic region is short and made of 47 residues,
and is ~10 KDa in size. It is also the most highly conserved region between the human
and the mouse (Monney et al., 2002). Human KIM-1 has 2 splice variants that differ in
the cytoplasmic domain; KIM-1a, consisting of 339 amino acids, is mainly expressed in
the liver, and has no tyrosine kinase phosporylation site; KIM-1b (referred to as KIM-1 in
this literature), consisting of 359 amino acids, is mainly expressed in the kidney, and has
2 highly conserved tyrosine residues and a predicted tyrosine kinase phosporylation motif
at position 350 (Zhang et al., 2007). The extracellular region of KIM-1 can be cleaved at
a proteolytic site close to transmembrane domain; thus shedding a physiologically active
soluble protein of ~90kDa into the extracellular space. This carries a great clinical
significance, as the ectodomain serves as a renal injury marker. The cells expressing
KIM-1 display constitutive shedding of the ectodomain (Bailly et al., 2002). The
shedding was inhibited by a broad-spectrum matrix metalloproteinase (MMP) inhibitor or
by blocking of the proteoletic site by a site-specific antibody (Bailly et al., 2002). Thus,
the cleavage of the extracellular domain is believed to be MMP mediated in vivo. Yet, a
separate study has also shown that the constitutive ectodomain shedding is mediated by
the activation of extra cellular signal regulated kinases (ERK) activation, and the
shedding is accelerated by the activation of p38 mitogen activated protein (MAP) kinase,
suggesting endogenous shedding is regulated. The secondary structure (and not the
amino acid sequence) in the juxtamembrane region is important for the shedding of the
ectodomain (Zhang et al., 2007).
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Figure 6: Structure of KIM-1. Adopted from (Waanders et al., 2009)

2.9.2 Expression of KIM-1
KIM-1 was first identified and characterized in 1998. It was noted that KIM-1
was not expressed in healthy murine kidney, but was abundantly expressed after different
direct or indirect renal injuries (Ichimura et al., 1998). Similar findings were observed for
human KIM-1 expression. While KIM-1 was undetectable in healthy human urine, it was
abundant in patients suffering from various primary and secondary kidney injuries,
allograft transplantation, and renal cell carcinoma. On further examination, with double
labeling with aquaporin-1 (a marker for renal tubules), it was observed that KIM-1 was
co-expressed with aquaporin-1 and was predominantly expressed by the proximal tubular
epithelial cell (van Timmeren et al., 2007). KIM-1 is expressed on the apical membrane
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of the injured tubules (van Timmeren et al., 2007). The expression of murine KIM-1,
depending on the nature of the injury, varies between different segments of the proximal
tubule. In the renal ischemic model, the expression was predominantly from the S3
segment of the corticomedullary tubules (Chiusolo et al., 2011). In conditions like
polycystic kidney disease, where the injury is not primarily to the S3 segment, the
expression was observed from the mid-cortical and superficial tubules (van Timmeren et
al., 2006). However, in 90% of all the renal injuries, both acute and chronic, the
expression was predominantly from the S3 segment of the proximal tubules (van
Timmeren et al., 2007).

2.9.3 Function of KIM-1
KIM-1/TIM-1 has been a topic of extensive research over the past few years
because of its varied roles in the kidney and immune system. In the renal system, most of
the work is directed towards understanding KIM-1 as a sensitive renal injury marker.
Similarly, extensive research has been carried out by immunologists to understand the
role of TIM-1 in regulating the immune system; although a global knockout was without
effect for immune responses (Barlow et al., 2011). In the following sections, the role of
renal and extra renal functions of KIM-1/TIM-1 will be discussed in detail.

34

2.9.3.1 Renal functions of KIM-1
As mentioned earlier, the extracellular domain of KIM-1 is a receptor for PS. PS is
present in the inner surface of the cell membrane, but when cells undergo apoptosis, PS is
exposed on the outer surface. This is recognized by a scavenger receptor, which by
definition, recognizes the PS, or oxidized LDL, and mediates their uptake. In vitro studies
show rat tubular epithelial cells recognize the PS on the apoptotic cells, mediate its
uptake, and direct it towards lysosomal degradation (Ichimura et al., 2008). Thus, the
KIM-1 expressing epithelial cells act as ‘semi-professional’ phagocytes. Hence, KIM-1
expressing epithelial cells recognizes the ‘eat me’ signal from the apoptotic/necrotic cells,
and so should mediate uptake, degradation, and clearance of the tubule of the dead and
necrotic cells. The mechanism and role of KIM-1 in directing the apoptotic cells to the
lysosomal degradation is not clear yet, but it is proposed, KIM-1 may be a co-receptor in
mediating the uptake.
KIM-1 has also demonstrated protective functions in IRI. In a murine kidney IRI
model, administration of monoclonal antibody against KIM-1 (RMT-10 clone) to the
mice had a protective function (Nozaki et al., 2102). Similar results were also observed
after liver ischemia/reperfusion injuries (Ueno et al., 2008). However, other groups using
a different monoclonal antibody, directed towards different epitopes, failed to observe
similar results. Hence, it is speculated that blocking different epitopes on the KIM-1 may
lead to altered functions. Further studies are required to have a conclusive answer.
Early detection of renal injury has always been of great significance; it not only
reduces the mortality and morbidity related to ARF, but also reduces the cost of the
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treatment. Following an injury, renal cells are known to have altered expression or
secretion of some molecules. They have been exploited for their use as renal injury
markers. KIM-1, IL-18, MMP-9, osteopontin, clusterin, and NGAL are some of the
molecules to be studied for use as renal injury markers (Bonventre et al., 2010). The
ectodomain of KIM-1 shed to the extracellular space can be detected in the urine, and
serves as a non-invasive marker for renal injury, and has been validated for its sensitivity
and specificity (Vaidya et al., 2010). Urinary KIM-1 has the highest sensitivity and
specificity compared to all the other biomarkers of renal injury (Vaidya et al., 2010).
KIM-1 is more sensitive than traditional biomarkers like serum creatinine and blood urea
nitrogen (BUN) (Liangos et al., 2007). KIM-1 shedding has also been considered a good
prognostic marker of renal injury, where the reduced shedding in the urine signifies the
reduction of the renal injury.
KIM-1 is also proposed to be involved in development of interstitial fibrosis.
KIM-1 expression is observed around the atrophic tubules surrounding the fibrosis.
Although there is no proof of increased expression of KIM-1 leading to fibrosis, a
positive association between the KIM-1 expression and renal fibrosis exists (Kuehn et al.,
2002). However, positive significant association is observed with tubular KIM-1
expression and interstitial damage (fibrosis and macrophage infiltration).
Extensive KIM-1 expression and shedding is observed in clear-cell type renal
carcinoma (RCC). Though the tumor cells do not express KIM-1, abundant expression is
observed in the neighboring epithelial cells (Cuadros et al., 2013). Many hypotheses have
been proposed to explain the expression of KIM-1 in them. First, mechanical pressure
exerted by the rapidly dividing tumor cell may cause ischemia in the neighboring cell or
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may dedifferentiate them. Second, KIM-1 expressing cells may represent the early stages
of the RCC (Cuadros et al., 2013). Conclusive answers remain elusive. Since RCC is an
immunogenic tumor, KIM-1/TIM-1 may be involved in modulating the immunogenicity
of the tumor.
KIM-1 is expressed in the primary cilia of the proximal tubular epithelia cells
(Kotsis et al., 2007). Primary cilia play important and diverse functions in the cellular
signaling. Defects in the primary cilia, usually due to the mutations in the genes encoding
the ciliary proteins, are associated with diseases such as impaired mucociliary clearance,
situs inverses, hydrocephalus, obesity, infertility, and polycystic kidney disease (Singla
and Reiter, 2006). Autosomal dominant polycytic kidney (PKD) disease is usually
associated with the mutations in PKD-1 gene, which encodes polycystin-1, or PKD-2
encoding TRPP-2 (Wu and Somlo, 2000). Renal cilia are non-motile, and lead to an
increase in intracellular calcium in response to urine flow (Liu et al., 2003). It is now
known that KIM-1 interacts with TRPP2 (Kotsis et al., 2007) and is dependent on the
highly conserved tyrosine at 350 in the cytoplasmic tail, and mutation of the tyrosine
residue results in defect of intracellular calcium change in response to flow (Kotsis et al.,
2007). As KIM-1 holds structural homology to MaDCAM family of proteins, an
endothelial integrin and selectin receptor, it is proposed to be involved in cell-to-cell or
cell-to-matrix adhesion. The exact role of KIM-1 in this process is yet to be determined
(Gordon, 2002).
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2.9.3.2 Extra renal function of KIM-1
KIM-1, also known as HAVCR-1, is expressed in hepatocytes, and facilitates the cellular
entry of hepatitis A virus (Silberstein et al., 2001).
KIM-1, also known as TIM-1, belongs to TIM family of proteins, which consist
of TIM-1, TIM-3, and TMI-4 in humans, and 4 (TIM-2) members in mice. TIM plays
important and complex roles in regulating the immune system. It is involved in the T cell
activation differentiation, survival, and T cell tolerance (Rodriguez-Manzanet et al.,
2009). TIM-1 is expressed on the active CD4+ T cells, but not on the naïve cells. Post
differentiation, TIM-1 is predominantly expressed on TH-2 cells; whereas, TH-1 cells
show limited or no expression (Umetsu et al., 2005). On T cells, TIMs act as receptors.
TIM-4 present on the antigen presenting cells or dentritic cells is the ligand for TIM-1,
and mediates the differentiation of Th-2 cells (Meyers et al., 2005). TIM-3 is known to
bind to gelatin-9 and regulate the duration of response of Th-1 (Umetsu et al., 2005).
Initial studies in interval-specific congenic mice (HBA) (McIntire et al., 2001)
identified TIM-1 as a susceptible gene for asthma and hypersensitive airway disease.
TIM-1 plays an important role in regulating the TH-2 cell responses, and thus regulates
the airway inflammation by regulating the TH-2 response in the asthma mice model
(Sizing et al., 2007). Epidemiological studies have also established a relation between the
SNPs in TIM-1 gene to increased asthma and atopy (Graves et al., 2005).
KIM-1/TIM-1 is also known to play an important role in organ transplant
rejection. Anti-KIM-1/TIM-1 monoclonal antibody administered to mice before the
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cardiac allograft, reduced the rate of rejection; whereas, agonist KIM-1/TIM-1 antibody
increased the rate of organ transplant rejection in the murine allograft kidney
transplantation model. The above-mentioned studies and more similar studies depict a
very strong association of KIM-1/TIM-1 in modulating some elements of the immune
response in allograft tissue transplantation.
Cisplatin, a widely used chemotherapeutic agent, which is nephrotoxic, is also
ototoxic. In cisplatin treated mice, increased expression of KIM-1 was observed in
cochlear cells (Mukherjea et al., 2006). Possible cochlear injury molecule (CIM-1) is
being explored.

2.10 Role of Matrix metalloproteinase in KIM-1 cleavage and acute renal failure
Matrix metalloproteinases are groups of Zn dependent endopeptidases. They were first
discovered about 50 years ago in the metamorphosis of tadpole tail for their
collagenolytic activity, degrading the extra cellular matrix. To date, 28 MMPs have been
identified, which share structural similarities and a catalytic Zn+ domain (Rodriguez et
al., 2010). Based on their substrates, MMPs are divides as collagenase (MMP -1, -8 and 13), stromelysins (MMP- 3,-10 and -11), gelatinases (MMP -2 and -9), and membrane
type MMP (MT-MMP) (Back et al., 2010). MMPs and their natural inhibitors TIMPs are
under a strict regulation, and play important and varied roles ranging from embryonic
development to pathogenesis of various diseases. MMP-9 is also a predicted renal injury
marker (Han et al., 2008). Apart from their role in the pathogenesis of various renal
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diseases, as discussed in section 2.9.1, the KIM-1 ectodomain is known to be cleaved by
MMP (Bailly et al., 2002), which makes it even more important for this discussion.

Figure 7: the expression profile of MMPs and their natural inhibitors TIMPs. The figure
shows the complied data for the expression profile for different MMPs in relation to nephron in
kidney. * denotes upregulation of MMPs in different pathological conditions. Adopted from (Tan
and Lui, 2012)

Many recent studies have demonstrated the role of MMPs, especially MMP-2 and
MMP-9, in the pathogenesis of renal ischemia-reperfusion injury. An increased
expression of MMP-2 and MMP-9 has been observed after IRI (Basile et al., 2004, Caron
et al., 2005, Catania et al., 2007). However, as contradictory results have also been
reported, uncertainties still exist (Jain et al., 2000, Ziswiler et al., 2001, Bengatta et al.,
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2009). The extracellular domain shedding in P769 cells was inhibited by preincubating
the cells with broad-spectrum MMP inhibitor BB94 (Bailly et al., 2002); which suggested
the role of MMP in endogenous KIM-1 shedding. Further, experiments carried out in
primary tubular cell culture suggested the role of MMP-3 in KIM-1 shedding (Lim et al.,
2012). Yet another study suggested the role of membrane-type 1 MMP (MT-MMP1) in
KIM-1 shedding (Guo et al., 2012). These conflicting results suggest that MMP involved
in KIM-1 shedding is still unclear or more than one MMP may be involved in the KIM-1
shedding. Hence, as mentioned in section 1.3, one of the specific aims of this study is to
discover the MMP involved in the KIM-1 shedding in injured kidney.

2.11 Role of KIM-1 in apoptotic cell clearance and renal regeneration
The earlier sections discuss the role of apoptotic and necrotic cells in sustaining
inflammation during ARF, and the importance of rapid clearing of the necrotic and
apoptotic cells in renal regeneration. The role of professional phagocytes and nonprofessional phagocytes in clearing the apoptotic and necrotic cells has also been
discussed in section 2.6. The studies from our lab, using a rat ethanol injury model,
showed extensive renal damage with apoptotic bodies as determined by TUNEL staining
(Latchoumycandane C, unpublished data). He observed extensive neutrophil infiltration,
whereas macrophages at the site of injury were minimal. Similar findings of absence of
infiltrating macrophages have been reported (Waanders et al., 2010). Hence, with
absence of macrophages, the ‘semiprofessional phagocytes’ are all that can be involved
in rapid clearing of apoptotic/necrotic cells. As discussed in section 2.9.3, KIM-1 confers
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a phagocytic phenotype to the epithelial cells (Ichimura et al., 2008). Hence, KIM-1
might play role in clearing the apoptotic bodies and in turn, could contribute to
attenuating the inflammation, preventing further inflammation, stalling immunological
response, and remodeling and regeneration of kidney. Renal allograft kidney biopsies
showed increased expression of KIM-1; interestingly, increased expression of KIM-1 was
associated with better prognosis with allograft renal transplantation (Zhang et al., 2008b).
This demonstrates, KIM-1 may not just be a prognosis marker, but involved in the renal
repair and regeneration.
Hepatocyte growth factor (HGF), a well-characterized renal repair factor (Liu and
Yang, 2006), is known to be upregulated in the epithelial cells that phagocytosed
apoptotic cells. It was observed that over expressing KIM-1 in pig kidney epithelial cells
also demonstrated increased mRNA expression of HGF (Ichimura et al., 2008). This
suggests that KIM-1 expressing epithelial cells, apart from clearing the apoptotic bodies,
may be involved in the renal regeneration by secreting growth/reparative factors.
KIM-1 is expressed in dedifferentiating epithelial cells and co-localizes with the
other dedifferentiation markers. KIM-1 also shares spatial relationship with ostiopontin, a
protein expressed from the tubular epithelial cells involved in renal repair (de Borst et al.,
2007). All these observations point towards the role of KIM-1 as more than just a
biomarker or a silent observer in renal injury and repair, but rather, play a role in renal
repair.
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CHAPTER III
MATERIALS AND METHODS

3.1 Cell culture
Immortalized normal human proximal tubular epithelial (HK2) cells were
purchased from ATCC (# CRL-2190); were revived in Dulbecco’s minimum essential
medium- F12 (DMEM-F12), cell culture media (Media core, Cleveland Clinic
Foundation, Cleveland OH); supplemented with 10% v/v heat inactivated fetal bovine
serum, (FBS Sigma Aldrich St. Louis MO) and 10000 IU penicillin streptomycin, (Sigma
Aldrich St. Louis MO). The cells were cultured in controlled environment of 5% CO2 at
370C. The cells were cultured to 80% confluence before passaging.

3.2 Isolation of neutrophils
Blood was collected from healthy volunteers in blood collection bag with the anticoagulant, ACD. RBC, buffy coat, and plasma were separated by centrifugation for 20
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min at 1300 RPM using Beckmen Coulter Allegra X15 R tabletop swinging bucket
centrifuge. The buffy coat was carefully transferred to a different tube and diluted with
equal volume of Hanks balanced salt solution (HBSS) w/o Mg++, Ca++, or phenol red
(Cleveland clinic media core Cleveland OH). Equal volume of 3% dextran 500 (#31395,
Sigma Aldrich St. Louis MO) solution in 1.9% NaCl was added and mixed well. It was
left to stand in 40C for 45 minutes – 1 hour allowing the RBCs to settle to the bottom.
The supernatant, which mainly contains neutrophils and monocytes, was carefully
transferred to a different tube.

The netrophils/monocytes were precipitated by

centrifuging at 1100 rpm for 10 minutes in Beckmen Coulter Allegra X15 R tabletop
centrifuges with swinging buckets. The carry over RBCs were lysed in 0.2% NaCl
solution for 30 sec. Care was taken not to exceed the lysis over 30 sec. RBC free
neutrophil/monocyte were resuspended in HBSS and loaded on top of Ficoll-Plaque plus
(#17-1440-02, GE Life sciences, Pittsburgh PA) cushion in the ratio of 5:4 v/v.
Neutrophils were separated from the monocytes by centrifuging for 30 mins at 1100 rpm.
The neutrophils were counted using hemecytometry counter and 107 neutrophils were
resuspended in 1mL of HBSS and used for further experiments.

3.3 Western blotting for KIM-1
Western blotting was performed to analyze total KIM-1 expression in the HK2
cells, and ectodomain shedding into the conditioned media. The cells were harvested in
RIPA buffer with 10% v/v protinase inhibitor cocktail. The total protein content was
estimated by Bio-Rad DCTM protein assay kit (#500-0111 Bio-Rad, Hercules CA) using
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the manufactures protocol. 20µg of protein was mixed with the 2X Laemmli sample
buffer (#161-0737EDU Bio-Rad, Hercules CA) containing 0.5% β-mercaptoethanol and
boiled for 5 minutes at 950 C and loaded on to a 4-20% gradient Tris-HCl precast gel
(#345-0032 Bio-Rad, Hercules CA). The electrophoresis was carried out at 120 V for 2
hours. The proteins were transferred on to nitrocellulose membrane using iBlot dry
transfer system (Invitrogen Inc). The membrane was then blocked for 1 hour in 5% nonfat milk in PBST. Then the membrane was probed for KIM-1 using human anti-KIM-1
mouse monoclonal antibody (# MAB1750, R&D Minneapolis, MN) at the concentration
of 1:1000 in 5% non-fat milk in PBST overnight at 40C. The primary antibody was
decanted and washed with PBST for 10 minutes X 3 times followed by incubation with
HRP conjugated goat anti-mouse secondary antibody (# Bio-Rad, Hercules CA) in the
concentration of 1: 10000 in 5% non-fat milk in PBST for 1 hour at room temperature.
The membrane was washed with PBST for 15 minutes 3 times.

3.4 Analysis of surface expression of KIM-1 on HK2 cells and uptake of lipid
vesicles by FACS.
Flow cytometric analysis was utilized to quantify the surface expression and
ectodomain shedding of KIM-1 in HK2 cells. HK2 cells were grown in complete media
and at 70% confluence and serum starved overnight before treatment. Post treatment, the
cells were harvested in 1X trypsin EDTA (Media core, Cleveland Clinic, Cleveland OH).
The harvested cells were washed 3 times with filtered PBS (Sigma Aldrich, St Louis
MO) and blocked with 1% bovine serum albumin (BSA) in PBS for 30 minutes on ice.
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The cells were incubated with mouse monoclonal KIM-1 antibody (#MAB-1750 R&D
Minneapolis, MN) in the dilution of 1:100 v/v in 1% BSA for 30 minutes followed by
goat anti-mouse secondary antibody tagged with Alexa Fluor 488 IgG (#A-11029, Life
Technologies, Carlsbad, CA) in the dilution of 1:100 in 1% BSA in PBS for 30 minutes
to detect the surface KIM-1 expression. The cells were washed in PBS thrice after each
step and fixed with 4% parformaldehyde and stored in the same fluid at 40C until utilized
for flow analysis. 350000 cells were analyzed in FACScan (BD Biosciences). The live
cells were gated and the KIM-1 expression was analyzed using FlowJo software.
The uptake of lipid vesicles containing DiI (synthesis of unilayer lipid to be
explained in the next section) by HK2 cells used 3 hours incubation. The cells were
harvested as mentioned before and washed with 1% BSA in PBS X 3 times. Then cells
were resuspended in 300 µL of PBS and analyzed in FACScan (BD Bioscienses) in FL2
channel to detect the DiI taken up by the cells. The cells were gated for live cells and
analyzed by FlowJo software.

3.5 siRNA mediated KIM-1 knockdown
KIM-1 specific siRNA was purchased from Dharmacon (#L-019856-00-0005,
Thermo Fisher Scientific, Wlatam MA) and reconstituted in siRNA buffer purchased
from Dharmacon (#B-002000-UB-100, Thermo Fisher Scientific, Wlatam MA). The
working concentration of 25 µM was used to transfect the cells. HK2 cells were cultured
in 6 well plates and allowed to reach ~ 50% confluence before transfection. Transfections
were carried out according to manufactures protocol using lipofectamin RNAimax
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(#13778030 Life technologies NY). The cells were incubated at 5% CO2 at 370C for 72
hours. The cells were harvested and analyzed for KIM-1 expression using western blots.

3.6 Unilamellar lipid vesicle synthesis
In a live cell, PS is present in the inner leaflet, while in cells undergoing
apoptosis/necrosis, the PS is exposed on the outer surface. The PS on the
apaototic/necrotic cells is recognized by scavenger receptors that mediates uptake of the
cells or particles. We mimicked this system by synthesizing unilamellar vesicle
containing PS. Mini extruder from Avantis polar lipids was used to synthesize these
liposomes. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) were purchased from Avanti polar
lipids, Alabaster AL (#770557 and 840034 respectively). POPC and POPS were mixed in
the molar ratio of 7:3.Vibrant DiI (Life technologies, Carlsbad CA) at the concentration
of 3:500 v/v was added and mixed well. The chloroform solvent was evaporated using a
liquid nitrogen evaporator. The pellets were hydrated in 500 µL of sterile HBSS. Lipid
vesicles were prepared by extrusion by repeatedly forcing the slurry through a 100 nm
membrane. The unilammelar vesicles contained either POPC alone, or POPC and POPS
in defined molar ratio, along with DiI.
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3.7 Quantification of shed KIM-1 by ELISA
The shed ectodomain of KIM-1 in conditioned media was quantified by ELISA.
Human KIM-1 ELISA duo kits were purchased from R&D (# DY1750 Minneapolis MN)
and the experiment was performed using manufacture’s protocol. In brief, Costar 96 well
EIA plate (# 3590 Costar, Cambridge MA) was coated with goat anti-human KIM-1
capture antibody by incubation at the concentration of 72 µg/mL in PBS overnight at
room temperature. Next day the plate was washed with PBS containing 0.5% Tween-20
(PBST) X 3 times followed by blocking with 1% BSA in PBS for 2 hours at room
temperature. 100 µL of sample diluted in 1% BSA in PBS was added and incubated at
room temperature for 1 hour. The washing step was repeated and 100 µL of biotinylated
goat anti-human detection antibody at the concentration of 72 µg/mL was added and
incubated for 1 hour at room temperature. The plate was washed again and 100 µL
Streptavidin-HRP in the dilution of 1:200 v/v was added and incubated for 20 minutes.
After washing, 100 µL substrate solutions (Thermo scientific, Wlatam MA) was added
and incubated for 20 minutes in the dark. The reaction was stopped by 50 µL 2N H2SO4
and the optical density was determined at 450 nm in multi well plate reader.

3.8 Gelatin zymogram to determine MMP activity
Precast gelatinase zymogram gels were purchased from Bio-Rad (#161-1167,
Bio-Rad, Hercules CA) to identify MMPs in cell culture and neutrophil supernatants. The
supernatants were mixed with equal volumes of 2X Liemmli buffer and loaded on to the
gel without boiling. After electrophoresis, the gel was renatured in 2.5% v/v Triton X 100
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(#T9284 Sigma Aldrich, St Louis MO) for 1 hour in room temperature. The gel was then
incubated in developing solution (# LC2671 Invitrogen, Carlsbad CA) for 48 hours at
room temperature. The developing solution was decanted and the gel was stained with 3
% Commassie blue for 30 minutes at room temperature. Then the gels were destained by
destaining buffer containing 40% methanol and 10% glacial acetic acid, until the bands
were clear.

3.9 Immunocytochemistry to quantify uptake of unilamellar phosphatidylserine
vesicles
HK-2 cells were cultured in 4 well chamber slides (# 70400 Lab-Tek®, Hatfield
PA) to 60 % confluence. The cells were treated with unilamellar vesicles in the dilution
of 3:100 v/v for 3 hours. After decanting the cell culture media, cells were washed in 1X
PBS followed by fixation in 4 % paraformaldehyde for 10 minutes. The HK-2 cells were
stained for KIM-1 using mouse monoclonal KIM-1 antibody (#MAB-1750 R&D
Minneapolis, MN) in the dilution of 1:100 v/v in 1% BSA for 30 minutes followed by
goat anti-mouse secondary antibody tagged with Alexa Fluor 488 IgG (#A-11029, Life
Technologies, Carlsbad, CA) in the dilution of 1:100 in 1% BSA in PBS for 30 minutes.
As the unilamellar vesicles were prestained with DiI; no additional staining was
necessary. The cells were washed with 1X PBS and mounted on with a covering slip
using mounting media containing DAPI (# H-500 Vector laboratories Peterborough UK).
The slides were sealed to prevent drying and viewed under Olympus fluorescent
microscope.
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CHAPTER IV
RESULTS

4.1 Activated neutrophils increase KIM-1 shedding in HK-2 cells
As we hypothesized, activated neutrophils mediate KIM-1 shedding in human
renal proximal tubular cells. The KIM-1 shedding was measured by 1) analyzing the
surface expression of KIM-1 by FACS and 2) detection and quantification of the shed
KIM-1 in the conditioned media by ELISA. Neutrophils were isolated freshly from
human blood as mentioned in section 3.2. Neutrophils (1 X 107) were resuspended in 1
mL of HBSS and were activated by 3 µM Platelet Activating Factor (PAF) for 1 hour at
room temperature with gentle agitation (Kuijpers et al., 1991). Other activation factors
like LPS was also tried, but discontinued, as neutrophils formed aggregates and adhered
to the walls of the microcentrifuge tubes. Supernatant from activated neutrophils was
used for the over-night treatment of HK2 cells (200 µL, for each well of a 6 well cell
culture plate). Supernatent from unactivated neutrophils was used as control. The relative
decrease in the surface expression of KIM-1 or increase in the shed KIM-1 into the
conditioned media was measured against the untreated cells. Figure 8A depicts the
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results from the FACS analysis. The untreated cells (control) show the maximum KIM-1
expression (shown in pink). As the cells were not permeabilised, the measured KIM-1 are
expected on the cell surface. HK-2 cells treated with activated neutrophil supernatents
show least relative fluorescent intensity denote the maximum shedding of KIM-1from the
surface (shown in green). The mean fluorescent intensity analyzed by FACS show
significant reduction on treatment with activated neutrophils compared to untreated HK-2
cells (Figure 8B). No significant changes in KIM-1 expression in HK-2 cells were
observed on treating HK-2 cells with supernatants form unactivated netrophils which
suggests the role of activation of neutrophils. Treatment with PAF, in absence of
neutrophils, did not show any effect on KIM-1 expression by HK2 cells (data not shown).
As the antibody detects only the N- terminal region, the reduction in KIM-1 expression
signifies the shedding of KIM-1 ectodomain. Unactivated neutrophils also mediate some
KIM-1 shedding (shown in blue); this is likely from unavoidable neutrophil activation.
To confirm that decreased surface expression of KIM-1was due to the shedding of
the ectodomain, the shed ectodomain in the conditioned media was quantified by KIM-1
ELSIA. The results from ELISA are depicted in the Figure 8C. HK2 cells treated with
supernatants from activated neutrophils showed significant increase in KIM-1 shedding
into the conditioned media compared to untreated HK2 cells and HK-2 cells treated with
supernatants from unactivated neutrophis. However there is no significant difference in
KIM-1 shedding between untreated HK-2 cells and HK-2 cells treated with supernatants
from unactivated neutrophil.
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Figure 8: Activated neutrophils mediate KIM-1 ectodomain shedding in HK-2 cells. A)
Surface expression of KIM-1 was analyzed by FACS and 35,000 HK-2 cells were counted per
group. The relative fluorescent intensity profile is represented in the graph. B) The bar diagram
shows the mean relative fluorescent intensity values from 4 independent experiments. HK-2 cells
treated with supernatants from activated neutrophils show significant reduction in the mean
fluorescent intensity value of KIM-1 compared to untreated cells, suggesting KIM-1 shedding
mediated by activated neutrophils C) The shed KIM-1 ectodomain into conditioned media was
quantified by ELISA. HK-2 cells treated with supernatants from activated neutrophils show
significant increase in the KIM-1 compared to untreated HK-2 cells or HK-2 cells treated with
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supernatants from unactivated neutrophils . The data are expressed as mean ± SEM (n=4), p ˂
0.05 was considered as significant.

4.2 Phosphatidylserine dependent uptake of lipid vesicles

Figure 9: Immunofluorescence showing PS dependent uptake of lipid vesicles. HK-2 cells
were treated with unilamellar lipid vesicles containing POPC and POPS in defined molar ratios
and DiI. The pictures were taken at 60X maginifcation. HK-2 cells were also stained for KIM1(green fluorescence) A) HK2 cells treated with liposomes containing only POPC, shown no red
florescence indicating the absence of uptake of vesicles. B) HK2 cells treated with liposome
contain POPS show red fluorescence indicating PS dependent uptake of vesicles.

Unilamellar lipid vesicles, containing POPC and POPS in defined molar ratios
and labeled with Vibrant DiI, cell labeling solution (Life technologies Carlsbad CA) ,
were prepared as explained in section 3.6. The uptake of unilamellar lipid vesicles was
examined by FACS (Figure 10), and immunofluorescence (Figure 9). To identify the
uptake of unilamellar vesicles by immunofluorecence, HK2 cells cultured to 60%
confluence in a 4 well chamber slide were treated for 3 hours with lipid vesicles
containing only POPC, or, vesicles containing POPC + POPS in molar ratios of 7:3. The
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HK2 cells treated with lipid vesicles containing no POPS show no red fluorescence
suggesting the absence of uptake of the lipid vesicles (Figure 9A). Whereas HK-2 cells
treated with lipid vesicles containing POPS (Figure 9A) show red fluorescence
suggesting uptake of lipid vesicles.

Figure 10: Phospatidylserine dependent uptake of lipid vesicles in HK-2 cells. Uptake of
unilammelar vesicles by HK-2 cells was analyzed by FACS and 35,000 HK-2 cells were counted
per group. HK-2 cells treated vesicles containing PS (red) show increased amount of relative
fluorescent intensity compared to HK-2 cells treated with vesicles without PS (blue), suggests PS
dependent uptake of lipid vesicles in HK2 cells.

The uptake of PS vesicles was also quantified by FACS.

HK2 cells grown to

80% confluence were treated with unilamellar lipid vesicles consisting of POPC alone or
vesicles containing POPC and POPS in the ratio of 7:3 for 3 hours in the dilution of 1 to
100 in DMEM-F12 media. The cells were harvested with trypsin EDTA and the excess
lipids in the media were removed with 1% BSA in PBS and subjected to FACS analysis.
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The cells treated with liposomes containing only POPC (shown in blue), show the least
amount of relative fluorescent intensity, signifying minimal or no lipid vesicle uptake.
Similarly, lipid vesicles containing PS (shown in red), show increased relative amount of
relative fluorescent intensity, suggesting uptake of unilamellar lipid vesicles. Untreated
cells (shown in green) served as control. This data suggests that uptake of lipid vesicles is
PS dependent and the physiological uptake of apoptotic bodies is successfully mimicked.

4.3 The uptake of unilamellar lipid vesicles containing phospatidylserine is KIM-1
mediated
The above results show that uptake of lipid vesicles was PS dependent. Hence we
wanted to examine if the KIM-1, a scavenger receptor, had any role in its uptake. To do
this, a transient siRNA mediated KIM-1 knockdown in HK2 cells was created. The
siRNA mediated KIM-1 knockdown was confirmed by western blotting which was
probed for KIM-1. The results are depicted in Figure 11. Lane 1, 2 and 3 show KIM-1
expression in untreated cell, cells treated with transfection reagent, Lipofectamin 2000,
and non-specific siRNA control respectively. Lane 4 and 5 shows KIM-1expression in
HK-2 cells treated with KIM-1 specific siRNA at the concentration of 15 µM and 25 µM
respectively. Lane 4 and 5 show appreciable reduction of KIM-1 (102 kDa) compared to
the untreated cells, which signifies successful siRNA mediated KIM-1 knockdown.
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Figure 11: Western blots showing successful siRNA mediated knockdown of KIM-1in HK2 cells. KIM-1 identified at 102kDa, show appreciable reduction in KIM-1 expression in KIM-1
siRNA transfected cells (lane 4 and lane 5) compared to untransfected cells (lane 1), non-specific
control siRNA transfected cells (lane 3) and transfection reagent control (lane 2), suggesting
successful knockdown of KIM-1 in HK2 cells using KIM-1 specific siRNA.

Further we examined the uptake of lipid vesicles containing PS in KIM-1
knockdown HK2 cells by FACS. As mentioned earlier, the cells were treated with the
lipid vesicles in the ratio of 1: 100 v/v for 3 hours. The cells were harvested and subjected
to FACS. The results of FACS analysis are shown in Figure 11. Control or untreated cells
(shown in green) show the maximum amount of relative fluorescent intensity, which
signify maximum lipid vesicle uptake. Cell treated with control siRNA (shown in blue)
do not show any reduction in the amount of relative fluorescent intensity. However, HK2 cells with KIM-1 knockdown (shown in pink and light blue), show significant reduction
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in the amount of relative fluorescent intensity. This result gives us concrete evidence of
KIM-1 mediated uptake of PS containing lipid vesicles. As apoptotic cells express PS on
their surface, this result suggests KIM-1 mediated uptake apoptotic cells by renal tubular
epithelial cells.

Figure 12: KIM-1 mediated uptake of PS vesicles by HK-2 cells. Uptake of unilammelar
vesicles by HK-2 cells was analyzed by FACS and 35,000 HK-2 cells were counted per group.
Relative fluorescent intensity profile in FL2 channel is represented in the graph. HK-2 cells
lacking KIM-1 (shown in pink and blue) show reduced amount of relative fluorescent intensity
compared to control (shown in green) or HK-2 cells transfected with control siRNA (shown in
blue) which suggests KIM-1 dependent uptake of PS vesicles.
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4.4 Activated neutrophils reduces phospatidylserine liposome uptake in HK-2 cells
by increasing the KIM-1 shedding
In section 4.2 we observed an increase in KIM-1ectodomain shedding mediated
by activated neutrophils. It is also known the PS binding site is situated in the ectodomain
of KIM-1. Hence, effect of loss of KIM-1 ectodoamin on uptake of PS containing
unilamellar vesicles was tested. HK2 cells were cultured to 80% confluence and treated
overnight with the supernatant from neutrophils activated by 3 µM PAF. These cells were
treated with PS containing unilamellar lipid vesicles. The cells were harvested with
trypsin EDTA and washed with 1% BSA before the cells were fixed using 4%
paraformaldehyde and analyzed by FACS. The results are depicted in Figure 13.

Figure 13: Activated neutrophils reduce PS liposome uptake in HK-2 cells. A) Uptake of PS
vesicles by HK-2 cells was analyzed by FACS and 35,000 HK-2 cells were counted per group.
The relative fluorescent intensity profile is represented in the graph. B) The bar graph represents
the mean relative fluorescent intensity values from 4 independent experiments. HK-2 cells treated
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with supernatants from activated neutrophils show significant reduction in relative fluorescent
intensity values, suggesting reduced uptake of PS liposomes, compared to untreated HK-2 cell,
and cells treated with supernatants from unactivated neutrophils. The data are expressed as mean
± SEM (n=4) p ˂ 0.05 was considered significant.

HK-2 cells treated with activated neutrophil supernatants (orange) show reduced relative
fluorescent intensity compared to untreated cells (blue) suggesting a reduction in the
uptake of PS containing lipid vesicles. The reduction in the lipid vesicle uptake is due to
increased shedding of KIM-1 ectodomain by activated neutrophils. Due to unavoidable
activation of neutrophils, unactivated neutrophils also cause some reduction in the lipid
vesicle uptake (green).

4.5 Neutrophils secrete Matrix metalloproteinas -9 upon activation
Activated neutrophils are known to secrete MMP-1, 2, 3, 7 and 9. Of theses,
MMP-9, a gelatinase, is most important and well studied (Allport et al., 2002). Gelatin
zymography explained in section 3.8 was employed to identify the MMP activity. The
cell culture supernatents from untreated cells served as a control to compare the MMP
activity in activated and unactivated neutrophil supernatants. The results from the gelatin
zymography are depicted in Figure 14. Lane 1, MMP activity from the supernatant of
untreated HK2 cells, shows minimal MMP-9 activity (92kDa). Lane 2 shows the MMP
activity in the supernatant form unactivated neutrophils. There is no increase in MMP-9
activity compared to control. However on activation of neutrophils with PAF, as in lane
3, shows appreciable increase in the MMP-9 activity. The specificity of the increased
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MMP activity was confirmed to be from MMP-9 by pre-treating the activated neutrophils
with specific MMP-9 inhibitor (# 1177749-58-4, EMD Millipore, Billerica, MA) as
shown in Lane 4. There is appreciable reduction in the band at 92 KDa, which suggest the
MMP activity from activated neutrophil is from MMP-9.

Figure 14:

Activated neutrophils secrete MMP-9. Supernatants from PAF activated

neutrophils, unactivated neutrophils, activated neutrophils treated with activated neutrophils, and
HK-2 cells were loaded on to gelatin zymogram. Shown activated neutrophils (lane 3) show
maximum MMP-9 activity. HK2 cell supernatants (lane 1) and unactivated neutrophils (lane 2),
show minimal or no active MMP-9. The MMP-9 activity is reduced on pretreating the activated
neutrophils with specific MMP-9 inhibitor (lane 4).
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4.6 Activated neutrophils mediate KIM-1 shedding via MMP-9
Bitamastat or BB94 (#2961 Tocris bioscience Bristol UK) is a broad spectrum
MMP inhibitor and this inhibits a range of MMPs when used at different concentrations.
To identify the MMP involved in KIM-1 shedding, activated neutrophils were treated
with different concentrations of BB-94 for 1 hour at room temperature; their releasates
were added to HK2 cells and surface KIM-1 expressions in these HK-2 cells were
quantified by FACS and shed KIM-1 in conditioned media by ELISA. Figure 14 shows
the results from the analysis. BB-94 when used at the concentrations that inhibit, MMP-1
and MMP 2 there was no inhibition of KIM-1 shedding. When used in higher
concentrations (50 nM) where MMP-1, -2, -9, - 7 and -3 were inhibited, inhibition of
KIM-1 shedding was complete. Finally, a specific MMP-9 inhibitor (# 1177749-58-4,
EMD Millipore, Billerica, MA) was used to confirm the role of MMP-9 in KIM-1
shedding. As shown in Figure 15A, HK-2 cells treated with supernatants from activated
neutrophils pretreated with MMP-9 inhibitor (shown in green) shows increased amount
of relative fluorescent intensity compared to cells treated with activated neutrophil
supernatant or pretreated with MMP-1and -2 inhibitor (black) suggesting inhibition of
KIM-1 shedding. Bar graph (Figure 15B) shows the mean relative fluorescent intensity
from 4 independent experiments. HK-2 cells treated with supernatants from activated
neutrophils pretreated with MMP-9 inhibitor show significant reduction in the KIM-1
shedding compared to HK-2 cells treated with supernatants from activated neutrophils
without MMP inhibitor. Figure 15C show the quantification of shed KIM-1 ectodomain
into the culture media by ELSIA..
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Figure 15: Pretreatment of activated neutrophils with MMP-9 inhibitor inhibits KIM-1
shedding in HK2 cells. A) Surface expression of KIM-1 was analyzed by FACS and 35,000 HK2 cells were counted per group. The relative fluorescent intensity profile is represented in the
graph. B) The bar diagram shows the mean relative fluorescent intensity values from 4
independent experiments. HK-2 cells treated with activated neutrophils show significant
reduction in the KIM-1 expression and the shedding is significantly inhibited on pre-treating the
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activated neutrophils with specific MMP-9 inhibitor. Pre-treating the activated neutrophils with
MMP-1 and MM-2 inhibitor show now change in the KIM-1 expression. C) The shed KIM-1
ectodomain was quantified by ELISA. Shed KIM-1 in conditioned media quantified by ELISA.
The data are expressed as mean ± SEM (n=4), p ˂ 0.05 was considered significant.

A significant reduction in the shedding of KIM-1 ectodomain is observed on
treating the HK-2 cells with activated neutrophils + MMP-9 inhibitor compared to
activated neutrophils without MMP-9 inhibitor. However, HK-2 cells treated with MMP
inhibitors did not show any changes in the surface expression of KIM-1, suggesting that
the MMPs involved in KIM-1 ectodomain shedding are secreted by activated neutrophils
and not by HK-2 cells (data not shown). According to our findings, even though MMP-9
secreted from activated neutrophils predominantly mediates KIM-1 ectodomain
shedding, the role of other MMPs cannot be neglected.

4.7 Inhibiting secreted MMP-9 increases the uptake of vesicles containing
phosphatidylserine in HK-2 cells
As discussed in section 4.6, we observed a significant reduction in the KIM-1
ectodomain shedding on inhibiting the secreted MMP-9 from activated neutrophils. As
the KIM-1 ectodomain contains the PS binding site and is involved in the uptake of the
unilamellar vesicles containing PS, we analyzed the effect of inhibiting MMP-9 in
activated neutrophils on PS vesicle uptake in HK-2 cells by FACS. The results from the
FACS analysis are represented in Figure 16. As described in section 3.4, HK-2 cells
cultured to 80 % confluence were treated with activated neutrophils with or with not

63

pretreating them with specific MMP-9 inhibitor followed by treatment with unilamellar
lipid vesicles containing PS. HK-2 cells treated with activated neutrophils show
significant reduction in the amount of relative fluorescent intensity, suggesting reduced
uptake of vesicles (green) compared to untreated cells (blue). On inhibiting MMP-9 in
activated neutrophils, the amount of relative fluorescent intensity significantly increases,
suggesting the regain of the lipid uptake capacity by HK-2 cells (orange). Inhibition of
MMP-9 inhibits the shedding of KIM-1 ectodomain, which leads to the regain of the
phogocytic property of HK-2 cells.

Figure 16: Inhibition of activated neutrophil secreted MMP-9 increases the uptake of
unilamellar PS vesicles in HK-2 cells. A) Uptake of PS vesicles by HK-2 cells was analyzed by
FACS and 35,000 HK-2 cells were counted per group. The relative fluorescent intensity profile is
represented in the graph. B) The bar diagram shows the mean relative fluorescent intensity values
from 4 independent experiments. HK-2 cells on treatment with supernatants from activated
neutrophils pretreated with specific MMP-9 inhibitor show significant increase in uptake of
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unilamellar vesicles containing PS compared to HK-2 cells treated with supernatants from
activated neutrophils. There is also significant reduction in the uptake of PS vesicles in HK-2
cells treated with supernatents from activated neutrophils comaperd to untreated HK-2 cells.The
data are expressed as mean ± SEM (n=4), p ˂ 0.05 was considered significant.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Conclusions
KIM-1, a sensitive, non-invasive urinary biomarker for kidney injury is also
suggested to play a role in ARF pathogenesis, renal repair, and regeneration. In this
study, we have examined the interaction of activated neutrophils with KIM-1 on HK-2
cells, relevant to its possible effects on kidney regeneration after acute injury. We have
demonstrated activated neutrophils mediate significant KIM-1 ectodomain shedding in
HK-2 cells. Activated neutrophils are known to secrete many proteases including MMPs.
We have demonstrated a significant reduction in the KIM-1 ectodomain shedding in HK2 cells on pretreating the activated neutrophils with a specific MMP-9 inhibitor,
suggesting the role of neutrophil secreted MMP-9 in KIM-1 shedding. Even though role
of other MMPs cannot be neglected, we have demonstrated that shedding of KIM1ectodomain is predominantly by MMP-9 mediated.
KIM-1 is a scavenger receptor i.e. epithelial cells expressing KIM-1 obtain the
properties of ‘semi-professional’ phagocytes. KIM-1 expressing epithelial cells
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recognizes the PS on apoptotic/necrotic cells and mediates its uptake and directs it to
degradation in lysosome. Rapid clearing of apoptotic/necrotic cells is necessary to
prevent further inflammation and renal regeneration. We examined the neutrophil
mediated KIM-1 shedding on the ability to take up the PS containing unilamellar vesicles
which mimicked this process of apoptotic/necrotic cell uptake by renal tubular epithelial
cells. In this study we have demonstrated a reduction in PS vesicle uptake by HK-2 cells
by materials released from activated neutrophils. Inhibiting KIM-1 shedding in HK-2
cells by inhibiting neutrophil secreted MMP-9 prevents the neutrophil mediated loss of
PS vesicle uptake capacity. Thus we conclude, KIM-1 may play a role in renal repair and
regeneration by rapid clearing of apoptotic/necrotic cells from the lumen and preventing
the shedding of KIM-1 by inhibiting MMP-9 form the neutrophils may hasten the renal
regeneration.
5.2 Future directions
In this in-vitro study we have successfully demonstrated the role of activated
neutrophils in KIM-1 shedding and its effects on uptake of apoptotic bodies. These
results should be further validated in a mouse model. Though TIM-1(-/-) mouse has
failed to show any changes in the phenotype, mice lacking renal KIM-1/TIM-1 will help
to provide a better understanding of role of KIM-1 in renal pathogenesis and repair. A
neutrophil depletion model will provide a better understanding of the interaction of
neutrophils with KIM-1. These studies will provide us with an opportunity to develop
treatment modalities, which involves prevention of KIM-1 shedding and hastening the
renal recovery.

67

REFERENCES
ABBATE, M., BONVENTRE, J. V. & BROWN, D. 1994. The microtubule network of
renal epithelial cells is disrupted by ischemia and reperfusion. Am J Physiol, 267,
F971-8.
ACHESON, A., SUNSHINE, J. L. & RUTISHAUSER, U. 1991. NCAM polysialic acid
can regulate both cell-cell and cell-substrate interactions. J Cell Biol, 114, 143-53.
AKCAY, A., NGUYEN, Q. & EDELSTEIN, C. L. 2009. Mediators of inflammation in
acute kidney injury. Mediators Inflamm, 2009, 137072.
ALI, T., KHAN, I., SIMPSON, W., PRESCOTT, G., TOWNEND, J., SMITH, W. &
MACLEOD, A. 2007. Incidence and outcomes in acute kidney injury: a
comprehensive population-based study. J Am Soc Nephrol, 18, 1292-8.
ALKHUNAIZI, A. M. & SCHRIER, R. W. 1996. Management of acute renal failure:
new perspectives. Am J Kidney Dis, 28, 315-28.
ALLGREN, R. L., MARBURY, T. C., RAHMAN, S. N., WEISBERG, L. S., FENVES,
A. Z., LAFAYETTE, R. A., SWEET, R. M., GENTER, F. C., KURNIK, B. R.,
CONGER, J. D. & SAYEGH, M. H. 1997. Anaritide in acute tubular necrosis.
Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med, 336, 82834.
ALLPORT, J. R., LIM, Y. C., SHIPLEY, J. M., SENIOR, R. M., SHAPIRO, S. D.,
MATSUYOSHI, N., VESTWEBER, D. & LUSCINSKAS, F. W. 2002.
Neutrophils from MMP-9- or neutrophil elastase-deficient mice show no defect in
transendothelial migration under flow in vitro. J Leukoc Biol, 71, 821-8.
ASANO, K., MIWA, M., MIWA, K., HANAYAMA, R., NAGASE, H., NAGATA, S. &
TANAKA, M. 2004. Masking of phosphatidylserine inhibits apoptotic cell
engulfment and induces autoantibody production in mice. J Exp Med, 200, 45967.
BACK, M., KETELHUTH, D. F. & AGEWALL, S. 2010. Matrix metalloproteinases in
atherothrombosis. Prog Cardiovasc Dis, 52, 410-28.
BADR, K. F. & ICHIKAWA, I. 1988. Prerenal failure: a deleterious shift from renal
compensation to decompensation. N Engl J Med, 319, 623-9.
BAILLY, V., ZHANG, Z., MEIER, W., CATE, R., SANICOLA, M. & BONVENTRE, J.
V. 2002. Shedding of kidney injury molecule-1, a putative adhesion protein
involved in renal regeneration. J Biol Chem, 277, 39739-48.

68

BARLOW, J. L., WONG, S. H., BALLANTYNE, S. J., JOLIN, H. E. & MCKENZIE, A.
N. 2011. Tim1 and Tim3 are not essential for experimental allergic asthma. Clin
Exp Allergy, 41, 1012-21.
BASILE, D. P., FREDRICH, K., WEIHRAUCH, D., HATTAN, N. & CHILIAN, W. M.
2004. Angiostatin and matrix metalloprotease expression following ischemic
acute renal failure. Am J Physiol Renal Physiol, 286, F893-902.
BASILE, D. P., LIAPIS, H. & HAMMERMAN, M. R. 1997. Expression of bcl-2 and bax
in regenerating rat renal tubules following ischemic injury. Am J Physiol, 272,
F640-7.
BASILE, D. P., MARTIN, D. R. & HAMMERMAN, M. R. 1998. Extracellular matrixrelated genes in kidney after ischemic injury: potential role for TGF-beta in
repair. Am J Physiol, 275, F894-903.
BAYLIS, C. & BRENNER, B. M. 1978. Modulation by prostaglandin synthesis
inhibitors of the action of exogenous angiotensin II on glomerular ultrafiltration in
the rat. Circ Res, 43, 889-98.
BELLOMO, R., RONCO, C., KELLUM, J. A., MEHTA, R. L., PALEVSKY, P. &
ACUTE DIALYSIS QUALITY INITIATIVE, W. 2004. Acute renal failure definition, outcome measures, animal models, fluid therapy and information
technology needs: the Second International Consensus Conference of the Acute
Dialysis Quality Initiative (ADQI) Group. Crit Care, 8, R204-12.
BENGATTA, S., ARNOULD, C., LETAVERNIER, E., MONGE, M., DE PRENEUF,
H. M., WERB, Z., RONCO, P. & LELONGT, B. 2009. MMP9 and SCF protect
from apoptosis in acute kidney injury. J Am Soc Nephrol, 20, 787-97.
BLANTZ, R. C. 1998. Pathophysiology of pre-renal azotemia. Kidney Int, 53, 512-23.
BOKEL, C. & BROWN, N. H. 2002. Integrins in development: moving on, responding
to, and sticking to the extracellular matrix. Dev Cell, 3, 311-21.
BONVENTRE, J. V. 1993. Mechanisms of ischemic acute renal failure. Kidney Int, 43,
1160-78.
BONVENTRE, J. V., VAIDYA, V. S., SCHMOUDER, R., FEIG, P. & DIETERLE, F.
2010. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol,
28, 436-40.
BONVENTRE, J. V. & ZUK, A. 2004. Ischemic acute renal failure: an inflammatory
disease? Kidney Int, 66, 480-5.
BORREGAARD, N. & COWLAND, J. B. 1997. Granules of the human neutrophilic
polymorphonuclear leukocyte. Blood, 89, 3503-21.
69

BRATER, D. C. 2002. Anti-inflammatory agents and renal function. Semin Arthritis
Rheum, 32, 33-42.
BRISKIN, M. J., MCEVOY, L. M. & BUTCHER, E. C. 1993. MAdCAM-1 has
homology to immunoglobulin and mucin-like adhesion receptors and to IgA1.
Nature, 363, 461-4.
CAMERON, J. S. 1988. Allergic interstitial nephritis: clinical features and pathogenesis.
Q J Med, 66, 97-115.
CARON, A., DESROSIERS, R. R. & BELIVEAU, R. 2005. Ischemia injury alters
endothelial cell properties of kidney cortex: stimulation of MMP-9. Exp Cell Res,
310, 105-16.
CATANIA, J. M., CHEN, G. & PARRISH, A. R. 2007. Role of matrix
metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol, 292,
F905-11.
CONGER, J. D. 1995. Interventions in clinical acute renal failure: what are the data? Am
J Kidney Dis, 26, 565-76.
COUNTS, R. S., NOWAK, G., WYATT, R. D. & SCHNELLMANN, R. G. 1995.
Nephrotoxicant inhibition of renal proximal tubule cell regeneration. Am J
Physiol, 269, F274-81.
CUADROS, T., TRILLA, E., VILA, M. R., DE TORRES, I., VILARDELL, J.,
MESSAOUD, N. B., SALCEDO, M., SARRO, E., LOPEZ-HELLIN, J.,
BLANCO, A., MIR, C., RAMON, Y. C. S., ITARTE, E., MOROTE, J. &
MESEGUER, A. 2013. Hepatitis A virus cellular receptor 1/kidney injury
molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis
A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a
predictive biomarker of tumour progression. Eur J Cancer.
DAEMEN, M. A., VAN 'T VEER, C., DENECKER, G., HEEMSKERK, V. H., WOLFS,
T. G., CLAUSS, M., VANDENABEELE, P. & BUURMAN, W. A. 1999.
Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J
Clin Invest, 104, 541-9.
DAVENPORT, A., WILL, E. J. & DAVISON, A. M. 1991. Continuous vs. intermittent
forms of haemofiltration and/or dialysis in the management of acute renal failure
in patients with defective cerebral autoregulation at risk of cerebral oedema.
Contrib Nephrol, 93, 225-33.
DE NICOLA, L., BLANTZ, R. C. & GABBAI, F. B. 1992. Nitric oxide and angiotensin
II. Glomerular and tubular interaction in the rat. J Clin Invest, 89, 1248-56.

70

DENTON, M. D., CHERTOW, G. M. & BRADY, H. R. 1996. "Renal-dose" dopamine
for the treatment of acute renal failure: scientific rationale, experimental studies
and clinical trials. Kidney Int, 50, 4-14.
FALK, R. J. & JENNETTE, J. C. 2010. ANCA disease: where is this field heading? J Am
Soc Nephrol, 21, 745-52.
FEEST, T. G., ROUND, A. & HAMAD, S. 1993. Incidence of severe acute renal failure
in adults: results of a community based study. BMJ, 306, 481-3.
FERENBACH, D. A., SHELDRAKE, T. A., DHALIWAL, K., KIPARI, T. M.,
MARSON, L. P., KLUTH, D. C. & HUGHES, J. 2012. Macrophage/monocyte
depletion by clodronate, but not diphtheria toxin, improves renal
ischemia/reperfusion injury in mice. Kidney Int, 82, 928-33.
FLORES, J., DIBONA, D. R., BECK, C. H. & LEAF, A. 1972. The role of cell swelling
in ischemic renal damage and the protective effect of hypertonic solute. J Clin
Invest, 51, 118-26.
FRANKLIN, S. S. & SMITH, R. D. 1986. A comparison of enalapril plus
hydrochlorothiazide with standard triple therapy in renovascular hypertension.
Nephron, 44 Suppl 1, 73-82.
FURUICHI, K., WADA, T., IWATA, Y., KITAGAWA, K., KOBAYASHI, K.,
HASHIMOTO, H., ISHIWATA, Y., TOMOSUGI, N., MUKAIDA, N.,
MATSUSHIMA, K., EGASHIRA, K. & YOKOYAMA, H. 2003. Gene therapy
expressing amino-terminal truncated monocyte chemoattractant protein-1
prevents renal ischemia-reperfusion injury. J Am Soc Nephrol, 14, 1066-71.
FURUICHI, K., WADA, T., IWATA, Y., SAKAI, N., YOSHIMOTO, K., KOBAYASHI
KI, K., MUKAIDA, N., MATSUSHIMA, K. & YOKOYAMA, H. 2002.
Administration of FR167653, a new anti-inflammatory compound, prevents renal
ischaemia/reperfusion injury in mice. Nephrol Dial Transplant, 17, 399-407
.
GAILIT, J., COLFLESH, D., RABINER, I., SIMONE, J. & GOLIGORSKY, M. S. 1993.
Redistribution and dysfunction of integrins in cultured renal epithelial cells
exposed to oxidative stress. Am J Physiol, 264, F149-57.
GAMBARO, G. & PERAZELLA, M. A. 2003. Adverse renal effects of antiinflammatory agents: evaluation of selective and nonselective cyclooxygenase
inhibitors. J Intern Med, 253, 643-52.
GLASSOCK, R. J. 2010. The pathogenesis of idiopathic membranous nephropathy: a 50year odyssey. Am J Kidney Dis, 56, 157-67.

71

GOLPON, H. A., FADOK, V. A., TARASEVICIENE-STEWART, L.,
SCERBAVICIUS, R., SAUER, C., WELTE, T., HENSON, P. M. & VOELKEL,
N. F. 2004. Life after corpse engulfment: phagocytosis of apoptotic cells leads to
VEGF secretion and cell growth. FASEB J, 18, 1716-8.
GORDON, S. 2002. Pattern recognition receptors: doubling up for the innate immune
response. Cell, 111, 927-30.
GRACIANO, M. L., MOUTON, C. R., PATTERSON, M. E., SETH, D. M., MULLINS,
J. J. & MITCHELL, K. D. 2007. Renal vascular and tubulointerstitial
inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible
ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol, 292,
F1858-66.
GRAVES, P. E., SIROUX, V., GUERRA, S., KLIMECKI, W. T. & MARTINEZ, F. D.
2005. Association of atopy and eczema with polymorphisms in T-cell
immunoglobulin domain and mucin domain-IL-2-inducible T-cell kinase gene
cluster in chromosome 5 q 33. J Allergy Clin Immunol, 116, 650-6.
GUO, L., TAKINO, T., ENDO, Y., DOMOTO, T. & SATO, H. 2012. Shedding of
kidney injury molecule-1 by membrane-type 1 matrix metalloproteinase. J
Biochem, 152, 425-32.
GUO, W. X., GHEBREHIWET, B., WEKSLER, B., SCHWEITZER, K. &
PEERSCHKE, E. I. 1999. Up-regulation of endothelial cell binding
proteins/receptors for complement component C1q by inflammatory cytokines. J
Lab Clin Med, 133, 541-50.
HAN, W. K., WAIKAR, S. S., JOHNSON, A., BETENSKY, R. A., DENT, C. L.,
DEVARAJAN, P. & BONVENTRE, J. V. 2008. Urinary biomarkers in the early
diagnosis of acute kidney injury. Kidney Int, 73, 863-9.
HAVASI, A. & BORKAN, S. C. 2011. Apoptosis and acute kidney injury. Kidney Int,
80, 29-40.
HIMMELFARB, J. 2009. Acute kidney injury in the elderly: problems and prospects.
Semin Nephrol, 29, 658-64.
HOSTE, E. A., CLERMONT, G., KERSTEN, A., VENKATARAMAN, R., ANGUS, D.
C., DE BACQUER, D. & KELLUM, J. A. 2006. RIFLE criteria for acute kidney
injury are associated with hospital mortality in critically ill patients: a cohort
analysis. Crit Care, 10, R73.
HSU, C. Y., MCCULLOCH, C. E., FAN, D., ORDONEZ, J. D., CHERTOW, G. M. &
GO, A. S. 2007. Community-based incidence of acute renal failure. Kidney Int,
72, 208-12.
72

HUMPHREYS, B. D., CZERNIAK, S., DIROCCO, D. P., HASNAIN, W., CHEEMA,
R. & BONVENTRE, J. V. 2011. Repair of injured proximal tubule does not
involve specialized progenitors. Proc Natl Acad Sci U S A, 108, 9226-31.
HUMPHREYS, B. D., VALERIUS, M. T., KOBAYASHI, A., MUGFORD, J. W.,
SOEUNG, S., DUFFIELD, J. S., MCMAHON, A. P. & BONVENTRE, J. V.
2008. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell, 2,
284-91.
ICHIMURA, T., ASSELDONK, E. J., HUMPHREYS, B. D., GUNARATNAM, L.,
DUFFIELD, J. S. & BONVENTRE, J. V. 2008. Kidney injury molecule-1 is a
phosphatidylserine receptor that confers a phagocytic phenotype on epithelial
cells. J Clin Invest, 118, 1657-68.
ICHIMURA, T., BONVENTRE, J. V., BAILLY, V., WEI, H., HESSION, C. A., CATE,
R. L. & SANICOLA, M. 1998. Kidney injury molecule-1 (KIM-1), a putative
epithelial cell adhesion molecule containing a novel immunoglobulin domain, is
up-regulated in renal cells after injury. J Biol Chem, 273, 4135-42.
ICHIMURA, T., BROOKS, C. R. & BONVENTRE, J. V. 2012. Kim-1/Tim-1 and
immune cells: shifting sands. Kidney Int, 81, 809-11.
ICHIMURA, T., MAIER, J. A., MACIAG, T., ZHANG, G. & STEVENS, J. L. 1995.
FGF-1 in normal and regenerating kidney: expression in mononuclear, interstitial,
and regenerating epithelial cells. Am J Physiol, 269, F653-62.
ISHIBASHI, N., WEISBROT-LEFKOWITZ, M., REUHL, K., INOUYE, M. &
MIROCHNITCHENKO, O. 1999. Modulation of chemokine expression during
ischemia/reperfusion in transgenic mice overproducing human glutathione
peroxidases. J Immunol, 163, 5666-77.
ISHIKAWA, K., MAY, C. N., GOBE, G., LANGENBERG, C. & BELLOMO, R. 2010.
Pathophysiology of septic acute kidney injury: a different view of tubular injury.
Contrib Nephrol, 165, 18-27.
JAIN, S., BICKNELL, G. R. & NICHOLSON, M. L. 2000. Molecular changes in
extracellular matrix turnover after renal ischaemia-reperfusion injury. Br J Surg,
87, 1188-92.
KELLUM, J. A., ANGUS, D. C., JOHNSON, J. P., LEBLANC, M., GRIFFIN, M.,
RAMAKRISHNAN, N. & LINDE-ZWIRBLE, W. T. 2002. Continuous versus
intermittent renal replacement therapy: a meta-analysis. Intensive Care Med, 28,
29-37.
KELLY, K. J., PLOTKIN, Z. & DAGHER, P. C. 2001. Guanosine supplementation
reduces apoptosis and protects renal function in the setting of ischemic injury. J
Clin Invest, 108, 1291-8.

73

KELLY, K. J., WILLIAMS, W. W., JR., COLVIN, R. B. & BONVENTRE, J. V. 1994.
Antibody to intercellular adhesion molecule 1 protects the kidney against
ischemic injury. Proc Natl Acad Sci U S A, 91, 812-6.
KELLY, K. J., WILLIAMS, W. W., JR., COLVIN, R. B., MEEHAN, S. M., SPRINGER,
T. A., GUTIERREZ-RAMOS, J. C. & BONVENTRE, J. V. 1996. Intercellular
adhesion molecule-1-deficient mice are protected against ischemic renal injury. J
Clin Invest, 97, 1056-63.
KERR, J. F., WYLLIE, A. H. & CURRIE, A. R. 1972. Apoptosis: a basic biological
phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 26,
239-57.
KOTSIS, F., NITSCHKE, R., BOEHLKE, C., BASHKUROV, M., WALZ, G. &
KUEHN, E. W. 2007. Ciliary calcium signaling is modulated by kidney injury
molecule-1 (Kim1). Pflugers Arch, 453, 819-29.
KREIDBERG, J. A. & SYMONS, J. M. 2000. Integrins in kidney development, function,
and disease. Am J Physiol Renal Physiol, 279, F233-42.
KUEHN, E. W., PARK, K. M., SOMLO, S. & BONVENTRE, J. V. 2002. Kidney injury
molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal
Physiol, 283, F1326-36.
KUIJPERS, T. W., TOOL, A. T., VAN DER SCHOOT, C. E., GINSEL, L. A.,
ONDERWATER, J. J., ROOS, D. & VERHOEVEN, A. J. 1991. Membrane
surface antigen expression on neutrophils: a reappraisal of the use of surface
markers for neutrophil activation. Blood, 78, 1105-11.
LAFRANCE, J. P. & MILLER, D. R. 2010. Acute kidney injury associates with
increased long-term mortality. J Am Soc Nephrol, 21, 345-52.
LAMEIRE, N., VAN BIESEN, W. & VANHOLDER, R. 2005. Acute renal failure.
Lancet, 365, 417-30.
LAUBER, K., BLUMENTHAL, S. G., WAIBEL, M. & WESSELBORG, S. 2004.
Clearance of apoptotic cells: getting rid of the corpses. Mol Cell, 14, 277-87.
LEAF, A. 1959. Maintenance of concentration gradients and regulation of cell volume.
Ann N Y Acad Sci, 72, 396-404.
LEE, S., HUEN, S., NISHIO, H., NISHIO, S., LEE, H. K., CHOI, B. S., RUHRBERG,
C. & CANTLEY, L. G. 2011. Distinct macrophage phenotypes contribute to
kidney injury and repair. J Am Soc Nephrol, 22, 317-26.
LI, L., HUANG, L., SUNG, S. S., VERGIS, A. L., ROSIN, D. L., ROSE, C. E., JR.,
LOBO, P. I. & OKUSA, M. D. 2008. The chemokine receptors CCR2 and
CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemiareperfusion injury. Kidney Int, 74, 1526-37.
74

LIANGOS, O. 2012. Drugs and AKI. Minerva Urol Nefrol, 64, 51-62.
LIANGOS, O., PERIANAYAGAM, M. C., VAIDYA, V. S., HAN, W. K., WALD, R.,
TIGHIOUART, H., MACKINNON, R. W., LI, L., BALAKRISHNAN, V. S.,
PEREIRA, B. J., BONVENTRE, J. V. & JABER, B. L. 2007. Urinary N-acetylbeta-(D)-glucosaminidase activity and kidney injury molecule-1 level are
associated with adverse outcomes in acute renal failure. J Am Soc Nephrol, 18,
904-12.
LIGHTSTONE, L. 2010. Lupus nephritis: where are we now? Curr Opin Rheumatol, 22,
252-6.
LIM, A. I., CHAN, L. Y., LAI, K. N., TANG, S. C., CHOW, C. W., LAM, M. F. &
LEUNG, J. C. 2012. Distinct role of matrix metalloproteinase-3 in kidney injury
molecule-1 shedding by kidney proximal tubular epithelial cells. Int J Biochem
Cell Biol, 44, 1040-50.
LINAS, S. L., WHITTENBURG, D., PARSONS, P. E. & REPINE, J. E. 1992. Mild
renal ischemia activates primed neutrophils to cause acute renal failure. Kidney
Int, 42, 610-6.
LINSHAW, M. A., MACALISTER, T. J., WELLING, L. W., BAUMAN, C. A.,
HEBERT, G. Z., DOWNEY, G. P., KOO, E. W. & GOTLIEB, A. I. 1991. Role of
cytoskeleton in isotonic cell volume control of rabbit proximal tubules. Am J
Physiol, 261, F60-9.
LIU, W., XU, S., WODA, C., KIM, P., WEINBAUM, S. & SATLIN, L. M. 2003. Effect
of flow and stretch on the [Ca2+]i response of principal and intercalated cells in
cortical collecting duct. Am J Physiol Renal Physiol, 285, F998-F1012.
LIU, Y. & YANG, J. 2006. Hepatocyte growth factor: new arsenal in the fights against
renal fibrosis? Kidney Int, 70, 238-40.
LU, L. H., OH, D. J., DURSUN, B., HE, Z., HOKE, T. S., FAUBEL, S. & EDELSTEIN,
C. L. 2008. Increased macrophage infiltration and fractalkine expression in
cisplatin-induced acute renal failure in mice. J Pharmacol Exp Ther, 324, 111-7.
MACDOWALL, P., KALRA, P. A., O'DONOGHUE, D. J., WALDEK, S., MAMTORA,
H. & BROWN, K. 1998. Risk of morbidity from renovascular disease in elderly
patients with congestive cardiac failure. Lancet, 352, 13-6.
MCINTIRE, J. J., UMETSU, S. E., AKBARI, O., POTTER, M., KUCHROO, V. K.,
BARSH, G. S., FREEMAN, G. J., UMETSU, D. T. & DEKRUYFF, R. H. 2001.
Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked
Tim gene family. Nat Immunol, 2, 1109-16.

75

MESSIER, B. & LEBLOND, C. P. 1960. Cell proliferation and migration as revealed by
radioautography after injection of thymidine-H3 into male rats and mice. Am J
Anat, 106, 247-85.
MEYERS, J. H., CHAKRAVARTI, S., SCHLESINGER, D., ILLES, Z., WALDNER,
H., UMETSU, S. E., KENNY, J., ZHENG, X. X., UMETSU, D. T., DEKRUYFF,
R. H., STROM, T. B. & KUCHROO, V. K. 2005. TIM-4 is the ligand for TIM-1,
and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol, 6,
455-64.
MIYAZAWA, S., WATANABE, H., MIYAJI, C., HOTTA, O. & ABO, T. 2002.
Leukocyte accumulation and changes in extra-renal organs during renal ischemia
reperfusion in mice. J Lab Clin Med, 139, 269-78.
MONNEY, L., SABATOS, C. A., GAGLIA, J. L., RYU, A., WALDNER, H.,
CHERNOVA, T., MANNING, S., GREENFIELD, E. A., COYLE, A. J., SOBEL,
R. A., FREEMAN, G. J. & KUCHROO, V. K. 2002. Th1-specific cell surface
protein Tim-3 regulates macrophage activation and severity of an autoimmune
disease. Nature, 415, 536-41.
MUKHERJEA, D., WHITWORTH, C. A., NANDISH, S., DUNAWAY, G. A., RYBAK,
L. P. & RAMKUMAR, V. 2006. Expression of the kidney injury molecule 1 in
the rat cochlea and induction by cisplatin. Neuroscience, 139, 733-40.
NADASDY, T., LASZIK, Z., BLICK, K. E., JOHNSON, L. D. & SILVA, F. G. 1994.
Proliferative activity of intrinsic cell populations in the normal human kidney. J
Am Soc Nephrol, 4, 2032-9.
NASH, K., HAFEEZ, A. & HOU, S. 2002. Hospital-acquired renal insufficiency. Am J
Kidney Dis, 39, 930-6.
NIGWEKAR, S. U. & WAIKAR, S. S. 2011. Diuretics in acute kidney injury. Semin
Nephrol, 31, 523-34.
OKUSA, M. D. 2002. The inflammatory cascade in acute ischemic renal failure.
Nephron, 90, 133-8.
OLIVER, J. A., MAAROUF, O., CHEEMA, F. H., MARTENS, T. P. & AL-AWQATI,
Q. 2004. The renal papilla is a niche for adult kidney stem cells. J Clin Invest,
114, 795-804.
PANNU, N. & NADIM, M. K. 2008. An overview of drug-induced acute kidney injury.
Crit Care Med, 36, S216-23.
PASCUAL, J., OROFINO, L., LIANO, F., MARCEN, R., NAYA, M. T., ORTE, L. &
ORTUNO, J. 1990. Incidence and prognosis of acute renal failure in older
patients. J Am Geriatr Soc, 38, 25-30.
76

PAWAR, S., KARTHA, S. & TOBACK, F. G. 1995. Differential gene expression in
migrating renal epithelial cells after wounding. J Cell Physiol, 165, 556-65.
PEARSON, A. M. 1996. Scavenger receptors in innate immunity. Curr Opin Immunol, 8,
20-8.
PEISER, L., MUKHOPADHYAY, S. & GORDON, S. 2002. Scavenger receptors in
innate immunity. Curr Opin Immunol, 14, 123-8.
PETRINEC, D., REILLY, J. M., SICARD, G. A., LOWELL, J. A., HOWARD, T. K.,
MARTIN, D. R., BRENNAN, D. C. & MILLER, S. B. 1996. Insulin-like growth
factor-I attenuates delayed graft function in a canine renal autotransplantation
model. Surgery, 120, 221-5; discussion 225-6.
PULSKENS, W. P., TESKE, G. J., BUTTER, L. M., ROELOFS, J. J., VAN DER POLL,
T., FLORQUIN, S. & LEEMANS, J. C. 2008. Toll-like receptor-4 coordinates the
innate immune response of the kidney to renal ischemia/reperfusion injury. PLoS
One, 3, e3596.
RABB, H., O'MEARA, Y. M., MADERNA, P., COLEMAN, P. & BRADY, H. R. 1997.
Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int,
51, 1463-8.
RAHMAN, A., KEFER, J., BANDO, M., NILES, W. D. & MALIK, A. B. 1998. Eselectin expression in human endothelial cells by TNF-alpha-induced oxidant
generation and NF-kappaB activation. Am J Physiol, 275, L533-44.
RAO, T. K. & FRIEDMAN, E. A. 1995. Outcome of severe acute renal failure in patients
with acquired immunodeficiency syndrome. Am J Kidney Dis, 25, 390-8.
RAVICHANDRAN, K. S. & LORENZ, U. 2007. Engulfment of apoptotic cells: signals
for a good meal. Nat Rev Immunol, 7, 964-74.
RODRIGUEZ-MANZANET, R., DEKRUYFF, R., KUCHROO, V. K. & UMETSU, D.
T. 2009. The costimulatory role of TIM molecules. Immunol Rev, 229, 259-70.
RODRIGUEZ, D., MORRISON, C. J. & OVERALL, C. M. 2010. Matrix
metalloproteinases: what do they not do? New substrates and biological roles
identified by murine models and proteomics. Biochim Biophys Acta, 1803, 39-54.
SANDOR, N., PAP, D., PRECHL, J., ERDEI, A. & BAJTAY, Z. 2009. A novel,
complement-mediated way to enhance the interplay between macrophages,
dendritic cells and T lymphocytes. Mol Immunol, 47, 438-48.

77

SAVILL, J. & FADOK, V. 2000. Corpse clearance defines the meaning of cell death.
Nature, 407, 784-8.
SHANKEL, S. W., JOHNSON, D. C., CLARK, P. S., SHANKEL, T. L. & O'NEIL, W.
M., JR. 1992. Acute renal failure and glomerulopathy caused by nonsteroidal antiinflammatory drugs. Arch Intern Med, 152, 986-90.
SHUSTERMAN, N., STROM, B. L., MURRAY, T. G., MORRISON, G., WEST, S. L.
& MAISLIN, G. 1987. Risk factors and outcome of hospital-acquired acute renal
failure. Clinical epidemiologic study. Am J Med, 83, 65-71.
SILBERSTEIN, E., DVEKSLER, G. & KAPLAN, G. G. 2001. Neutralization of
hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region
of HAV cellular receptor-1. J Virol, 75, 717-25.
SINGLA, V. & REITER, J. F. 2006. The primary cilium as the cell's antenna: signaling at
a sensory organelle. Science, 313, 629-33.
SIZING, I. D., BAILLY, V., MCCOON, P., CHANG, W., RAO, S., PABLO, L.,
RENNARD, R., WALSH, M., LI, Z., ZAFARI, M., DOBLES, M., TARILONTE,
L., MIKLASZ, S., MAJEAU, G., GODBOUT, K., SCOTT, M. L. & RENNERT,
P. D. 2007. Epitope-dependent effect of anti-murine TIM-1 monoclonal
antibodies on T cell activity and lung immune responses. J Immunol, 178, 224961.
SOLEZ, K., MOREL-MAROGER, L. & SRAER, J. D. 1979. The morphology of "acute
tubular necrosis" in man: analysis of 57 renal biopsies and a comparison with the
glycerol model. Medicine (Baltimore), 58, 362-76.
SPIEGEL, D. M., ULLIAN, M. E., ZERBE, G. O. & BERL, T. 1991. Determinants of
survival and recovery in acute renal failure patients dialyzed in intensive-care
units. Am J Nephrol, 11, 44-7.
STAR, R. A. 1998. Treatment of acute renal failure. Kidney Int, 54, 1817-31.
SU, E. W., LIN, J. Y. & KANE, L. P. 2008. TIM-1 and TIM-3 proteins in immune
regulation. Cytokine, 44, 9-13.
Standring S 2009. Gray's Anatomy 40th Edition, Churchill Livingstone Page 1226-1264
SUTTON, T. A., FISHER, C. J. & MOLITORIS, B. A. 2002. Microvascular endothelial
injury and dysfunction during ischemic acute renal failure. Kidney Int, 62, 153949.
TAN, R. J. & LIU, Y. 2012. Matrix metalloproteinases in kidney homeostasis and
diseases. Am J Physiol Renal Physiol, 302, F1351-61.

78

TANAKA, E. M. & REDDIEN, P. W. 2011. The cellular basis for animal regeneration.
Dev Cell, 21, 172-85.
TAYLOR, P. R., CARUGATI, A., FADOK, V. A., COOK, H. T., ANDREWS, M.,
CARROLL, M. C., SAVILL, J. S., HENSON, P. M., BOTTO, M. & WALPORT,
M. J. 2000. A hierarchical role for classical pathway complement proteins in the
clearance of apoptotic cells in vivo. J Exp Med, 192, 359-66.
TEXTOR, S. C., WIESNER, R., WILSON, D. J., PORAYKO, M., ROMERO, J. C.,
BURNETT, J. C., JR., GORES, G., HAY, E., DICKSON, E. R. & KROM, R. A.
1993. Systemic and renal hemodynamic differences between FK506 and
cyclosporine in liver transplant recipients. Transplantation, 55, 1332-9.
THADHANI, R., PASCUAL, M. & BONVENTRE, J. V. 1996. Acute renal failure. N
Engl J Med, 334, 1448-60.
THURMAN, J. M., LJUBANOVIC, D., ROYER, P. A., KRAUS, D. M., MOLINA, H.,
BARRY, N. P., PROCTOR, G., LEVI, M. & HOLERS, V. M. 2006a. Altered
renal tubular expression of the complement inhibitor Crry permits complement
activation after ischemia/reperfusion. J Clin Invest, 116, 357-68.
THURMAN, J. M., LUCIA, M. S., LJUBANOVIC, D. & HOLERS, V. M. 2005. Acute
tubular necrosis is characterized by activation of the alternative pathway of
complement. Kidney Int, 67, 524-30.
THURMAN, J. M., ROYER, P. A., LJUBANOVIC, D., DURSUN, B., LENDERINK, A.
M., EDELSTEIN, C. L. & HOLERS, V. M. 2006b. Treatment with an inhibitory
monoclonal antibody to mouse factor B protects mice from induction of apoptosis
and renal ischemia/reperfusion injury. J Am Soc Nephrol, 17, 707-15.
UCHINO, S., KELLUM, J. A., BELLOMO, R., DOIG, G. S., MORIMATSU, H.,
MORGERA, S., SCHETZ, M., TAN, I., BOUMAN, C., MACEDO, E., GIBNEY,
N., TOLWANI, A., RONCO, C., BEGINNING & ENDING SUPPORTIVE
THERAPY FOR THE KIDNEY, I. 2005. Acute renal failure in critically ill
patients: a multinational, multicenter study. JAMA, 294, 813-8.
UEDA, N. & SHAH, S. V. 2000. Tubular cell damage in acute renal failure-apoptosis,
necrosis, or both. Nephrol Dial Transplant, 15, 318-23.
UENO, T., HABICHT, A., CLARKSON, M. R., ALBIN, M. J., YAMAURA, K.,
BOENISCH, O., POPOOLA, J., WANG, Y., YAGITA, H., AKIBA, H.,
ANSARI, M. J., YANG, J., TURKA, L. A., ROTHSTEIN, D. M., PADERA, R.
F., NAJAFIAN, N. & SAYEGH, M. H. 2008. The emerging role of T cell Ig
mucin 1 in alloimmune responses in an experimental mouse transplant model. J
Clin Invest, 118, 742-51.

79

UMETSU, S. E., LEE, W. L., MCINTIRE, J. J., DOWNEY, L., SANJANWALA, B.,
AKBARI, O., BERRY, G. J., NAGUMO, H., FREEMAN, G. J., UMETSU, D. T.
& DEKRUYFF, R. H. 2005. TIM-1 induces T cell activation and inhibits the
development of peripheral tolerance. Nat Immunol, 6, 447-54.
VAIDYA, V. S., OZER, J. S., DIETERLE, F., COLLINGS, F. B., RAMIREZ, V.,
TROTH, S., MUNIAPPA, N., THUDIUM, D., GERHOLD, D., HOLDER, D. J.,
BOBADILLA, N. A., MARRER, E., PERENTES, E., CORDIER, A.,
VONDERSCHER, J., MAURER, G., GOERING, P. L., SISTARE, F. D. &
BONVENTRE, J. V. 2010. Kidney injury molecule-1 outperforms traditional
biomarkers of kidney injury in preclinical biomarker qualification studies. Nat
Biotechnol, 28, 478-85.
VAN TIMMEREN, M. M., VAN DEN HEUVEL, M. C., BAILLY, V., BAKKER, S. J.,
VAN GOOR, H. & STEGEMAN, C. A. 2007. Tubular kidney injury molecule-1
(KIM-1) in human renal disease. J Pathol, 212, 209-17.
WAANDERS, F., VAN TIMMEREN, M. M., STEGEMAN, C. A., BAKKER, S. J. &
VAN GOOR, H. 2010. Kidney injury molecule-1 in renal disease. J Pathol, 220,
7-16.
WALSH, F. S. & DOHERTY, P. 1997. Neural cell adhesion molecules of the
immunoglobulin superfamily: role in axon growth and guidance. Annu Rev Cell
Dev Biol, 13, 425-56.
WEI, Q. & DONG, Z. 2012. Mouse model of ischemic acute kidney injury: technical
notes and tricks. Am J Physiol Renal Physiol, 303, F1487-94.
WESTENFELDER, C. 2011. Earlier diagnosis of acute kidney injury awaits effective
therapy. Kidney Int, 79, 1159-61.
WILLINGER, C. C., SCHRAMEK, H., PFALLER, K. & PFALLER, W. 1992. Tissue
distribution of neutrophils in postischemic acute renal failure. Virchows Arch B
Cell Pathol Incl Mol Pathol, 62, 237-43.
WITZGALL, R., BROWN, D., SCHWARZ, C. & BONVENTRE, J. V. 1994.
Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in
the postischemic kidney. Evidence for a heterogenous genetic response among
nephron segments, and a large pool of mitotically active and dedifferentiated
cells. J Clin Invest, 93, 2175-88.
WU, G. & SOMLO, S. 2000. Molecular genetics and mechanism of autosomal dominant
polycystic kidney disease. Mol Genet Metab, 69, 1-15.
ZANARDO, G., MICHIELON, P., PACCAGNELLA, A., ROSI, P., CALO, M.,
SALANDIN, V., DA ROS, A., MICHIELETTO, F. & SIMINI, G. 1994. Acute

80

renal failure in the patient undergoing cardiac operation. Prevalence, mortality
rate, and main risk factors. J Thorac Cardiovasc Surg, 107, 1489-95.
ZHANG, B., RAMESH, G., UEMATSU, S., AKIRA, S. & REEVES, W. B. 2008a.
TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am
Soc Nephrol, 19, 923-32.
ZHANG, P. L., ROTHBLUM, L. I., HAN, W. K., BLASICK, T. M., POTDAR, S. &
BONVENTRE, J. V. 2008b. Kidney injury molecule-1 expression in transplant
biopsies is a sensitive measure of cell injury. Kidney Int, 73, 608-14.
ZHANG, Z., HUMPHREYS, B. D. & BONVENTRE, J. V. 2007. Shedding of the
urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP
kinases and juxtamembrane region. J Am Soc Nephrol, 18, 2704-14.
ZISWILER, R., DANIEL, C., FRANZ, E. & MARTI, H. P. 2001. Renal matrix
metalloproteinase activity is unaffected by experimental ischemia-reperfusion
injury and matrix metalloproteinase inhibition does not alter outcome of renal
function. Exp Nephrol, 9, 118-24.
ZUK, A., BONVENTRE, J. V., BROWN, D. & MATLIN, K. S. 1998. Polarity, integrin,
and extracellular matrix dynamics in the postischemic rat kidney. Am J Physiol,
275, C711-31.
ZUK, A., BONVENTRE, J. V. & MATLIN, K. S. 2001. Expression of fibronectin splice
variants in the postischemic rat kidney. Am J Physiol Renal Physiol, 280, F103753.
ZUK, A. & MATLIN, K. S. 2002. Induction of a laminin isoform and alpha(3)beta(1)integrin in renal ischemic injury and repair in vivo. Am J Physiol Renal Physiol,
283, F971-84.

81

